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ABSTRACT 
 
LAURENCE L. MILLER: Cannabinoid Modulation of the Behavioral Effects of 
Morphine 
(Under the direction of Linda A. Dykstra) 
  
 Researchers have demonstrated interactions between exogenously administered 
cannabinoid and opioid ligands on a variety on behavioral endpoints. The following 
studies extend these findings by examining the role of the endogenous cannabinoid 
system in the antinociceptive, and other behavioral effects of morphine.  
 The experiments in Chapter 2 use disruption of signaling via the type 1 
cannabinoid receptor (CB1) in order to examine the role of the endogenous cannabinoid 
system in the antinociceptive effects of morphine. The effects of morphine did not differ 
in CB1 KO and WT mice; however, a CB1 antagonist did attenuate the effects of 
morphine. This suggests that endogenous cannabinoid signaling via CB1 receptors 
modulates the antinociceptive effects of morphine, and CB1 KO mice may undergo 
developmental changes that mask this role. 
 The experiments described in Chapter 3 examine the consequences of the 
enhancement of endogenous cannabinoid signaling on the antinociceptive effects of 
morphine. This was accomplished by examining morphine alone and in combination with 
drugs that inhibit the degradation of the endogenous cannabinoid anandamide (AEA). 
Two well-established preclinical pain models, the hotplate assay and the acetic acid-
induced writhing assay, were used in these studies. The results demonstrate that 
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inhibition of the enzymatic breakdown of endogenous cannabinoids enhances the 
antinociceptive effects of morphine in the acetic acid-induced writhing assay, but not the 
hotplate assay. 
 Chapter 4 assesses morphine in combination with the same pharmacological 
manipulations of endogenous cannabinoid signaling that were described in Chapter 3. 
These experiments extend the previous results by examining these drug combinations in 
assays of pain-suppressed behavior and schedule-controlled behavior. The results provide 
evidence that, unlike direct CB1 agonists, drugs that alter endogenous cannabinoid levels 
specifically alter morphine’s antinociceptive effects. 
 The experimental results described in this dissertation suggest that the 
endogenous cannabinoid system plays a role in the antinociceptive effects of morphine. 
In addition, these findings show that this role is dependent on variables such as the nature 
of the noxious stimulus, and the means used to prevent endogenous cannabinoid 
degradation. Finally, these studies suggest that this enhancement of morphine’s 
behavioral effects is limited to antinociception. 
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PREFACE 
 This dissertation was prepared in accordance with the guidelines set forth by the 
University of North Carolina Graduate School. This dissertation consists of a general 
introduction, three chapters  of original data, and a general discussion chapter. Each 
original data chapter includes a unique abstract, introduction, results, and discussion 
section. A complete list of literature cited throughout the dissertation is included at the 
end of the document. References are listed in alphabetical order. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
Type 1 Cannabinoid Receptors, Anandamide and Related Constituents of the 
Endocannabinoid System 
 The cannabinoid system is composed of two confirmed receptors: the type 1 
(CB1) and type 2 (CB2) cannabinoid receptors. CB1 receptors are located throughout the 
nervous system and though CB2 receptors were initially thought to be located only on 
immune cells (Howlett et al., 2002; Pertwee, 2005), there is some evidence of wider 
distribution, including in the nervous system (Van Sickle et al., 2005; Beltramo et al., 
2006; Gong et al., 2006). CB1 receptors are g-protein-coupled (Gi/o) receptors that are 
primarily located presynaptically. Their activation results in decreased cyclic AMP 
(cAMP) production (Howlett et al., 2002) as well as direct inhibition of voltage-gated 
calcium channels (Chemin et al., 2001). An important consequence of these effects is 
retrograde modulation of synaptic activity through inhibition of neurotransmitter release 
from the presynaptic cell (Shen et al., 1996; Katona et al., 1999). CB2 receptors are 
coupled to similar signaling mechanisms, but do not alter the functioning of ion channels. 
Their role in the nervous system is less clear than that of CB1 receptors (Chin et al., 
2008).  
Anandamide (AEA) and 2-arachidonylglycerol (2-AG) are the most well 
characterized endogenous cannabinoids. They are not stored in vesicles, but are produced 
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as a result of activity-dependent post-synaptic calcium increases from the phospholipid 
precursors, N-arachidonoyl-phosphatidylethanolamine (NAPE) and 1,2-diacylglycerol 
(DAG), respectively. These post-synaptic calcium increases may come as a result of 
depolarization or recruitment from intracellular stores (Di Marzo, 2006). AEA has a 
higher affinity for CB1 than CB2 receptors and acts as a partial agonist. 2-AG binds to 
both receptors with lower affinity than AEA but acts as a full agonist (Mechoulam et al., 
1995; Di Marzo et al., 2005).  
After acting at presynaptic CB1 receptors, AEA is taken into the postsynaptic cell 
and broken down by fatty acid amide hydrolase (FAAH; Gulyas et al., 2004). 
Monoacylglycerol lipase (MAGL) metabolizes 2-AG into inactive constituents and this 
occurs presynaptically (for review, Piomelli, 2003; Gulyas et al., 2004). It has been 
confirmed that enzymatic breakdown of endocannabinoids occurs intracellularly, but 
there is controversy over whether endocannabinoid transport for this process occurs via 
an active or passive mechanism (Di Marzo, 2006). As would be predicted based on their 
relationship with AEA, FAAH and CB1 have complimentary post- and pre-synaptic 
distribution, respectively, throughout the nervous system (Egertová et al., 2003; Gulyas et 
al., 2004). 
 
 
Cannabinoid modulation of nociception  
 In the late 19
th
 century Dixon (1899) provided some of the first scientific evidence 
of the antinociceptive effects of cannabinoids when he demonstrated that dogs show a 
diminished response to pin pricks after inhaling marijuana smoke. Subsequent studies 
have demonstrated that drugs acting as cannabinoid agonists produce antinociception in 
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thermal (Lichtman and Martin, 1997; Welch et al., 1998), mechanical (Clayton et al., 
2002) and inflammatory (Calignano et al., 1998) acute pain models, as well as models of 
persistent pain (Tsou et al., 1996; Herzberg et al., 1997). In addition, it has been 
demonstrated that the administration of cannabinoids suppresses activity in pain circuits 
in response to a variety (thermal, chemical, and mechanical) of noxious stimuli 
(Hohmann et al., 1995, 1999; Martin et al., 1996). Research has also revealed that other 
behavioral effects occur as a result of the administration of cannabinoid agonists. 
Cannabinoid agonists produce catalepsy, inhibition of locomotor activity, and disruption 
of thermoregulation (Martin et al., 1991). Assessments of these three characteristics, 
along with antinociception, have come to be part of a behavioral screen that is known as 
the “cannabinoid tetrad.” Research suggests that these effects are primarily mediated by 
CB1 receptors. 
 More recently, manipulations of endogenous cannabinoid activity have garnered 
interest, and manipulations of AEA activity at CB1 receptors have been studied most 
extensively. There is evidence that AEA is synthesized in response to exposure to 
noxious stimuli, and acts at CB1 receptors to modulate pain (Walker et al., 1999; 
Mitrirattanakul et al., 2006; Jhaveri et al., 2006; Petrosino et al., 2007; Richardson et al., 
2008; Kaufmann et al., 2009). When administered systemically, AEA produces 
antinociception and other tetrad effects (Vivian et al., 1998; Adams et al., 1998); 
however, relative to exogenous cannabinoids such as 9-THC, these effects are 
diminished and brief. It is likely that this is due to the rapid uptake of AEA and its 
subsequent metabolism by FAAH. Consistent with this hypothesis, administration of an 
AEA reuptake blocker results in accumulation of AEA (Beltramo et al., 1997; Moore et 
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al., 2005) as well as enhancement of analgesia produced by systemic administration of 
AEA (Beltramo et al., 1997; Moore et al., 2005; La Rana et al., 2006). In addition, 
pharmacological inhibition of FAAH elevates AEA levels and produces CB1 dependent 
antinociception (Kathuria et al., 2003; Lichtman et al., 2004, 2008). Consistent with 
studies examining pharmacological inhibition of FAAH, FAAH knockout mice, have 
approximately 10-fold higher AEA levels relative to their WT littermates, have increased 
sensitivity to the antinociceptive effects of AEA and display reduced baseline pain 
sensitivity in the tail-immersion, hot plate, formalin and acetic acid models (Cravatt et al., 
2001; Lichtman et al., 2004, 2008; Wise et al., 2007). 
 Interestingly, manipulations such as pharmacological inhibition of FAAH 
typically produce antinociception in the absence of catalepsy, disruptions of locomotor 
activity and other effects associated with administration of CB1 agonists (Kathuria et al., 
2003; Jayamanne et al., 2006), though there is one report of decreased locomotor activity 
after the administration the AEA uptake inhibitor, AM404 (Giuffrida et al., 2000). 
 
Evidence of interactions of the cannabinoid and opioid systems 
 The cannabinoid and opioid systems are comparable in a variety of ways. Both 
include G-protein-coupled receptors that are similarly distributed throughout the CNS 
(Mailleux and Vanderhaeghen, 1992; Maekawa et al., 1994; Mansour et al., 1995; 
Arvidsson et al., 1995; Lichtman et al., 1996; Tsou et al., 1998; Chen et al., 2002; 
Cristino et al., 2006), and there is evidence of their co-localization (Rodriguez et al., 
2001; Salio et al., 2001). Activation of these receptors typically results in decreased 
synaptic activity (Howlett et al., 2002; Freund et al., 2003; Bodnar, 2009). In addition, 
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agonists at CB1 and opioid receptors produce similar behavioral effects that include 
antinociception (Cox and Welch, 2004; Fischer et al., 2008a), disruption of normal 
locomotor activity (Pascual et al., 2005; Smith et al., 2009), effects on food consumption 
(Järbe and DiPatrizio, 2005; Li et al., 2006), and interference with thermoregulation 
(Wang et al., 2008; Diaz et al., 2009). Moreover, agonists of both types of receptors serve 
as reinforcers in self-administration paradigms (Negus and Rice, 2008; Justinova et al., 
2008) and produce conditioned place preference (Braida et al., 2001; Carrigan and 
Dykstra, 2007).  
 Researchers have investigated the possibility that these systems interact and a 
number of studies have examined the analgesic effects of cannabinoid/opioid 
combinations. It is now well-established that administration of CB1 agonists enhance the 
antinociceptive effects of opioids (Welch and Stevens, 1992; Smith et al., 1994b, 2007; 
Pugh et al., 1996; Smith, 1998; Welch and Eads, 1999; Cichewicz and Welch, 2003; 
Cichewicz and McCarthy, 2003; Roberts et al., 2006; Cox et al., 2007). The potentiation 
of the antinociceptive effects of opioids is interesting at a basic science level and could 
also have clinical utility; however, evidence from other studies suggests that interactions 
between cannabinoid and opioid agonists are not limited to antinociception. Acutely 
administered CB1 agonists and morphine interact to alter locomotor activity (Ayhan et 
al., 1979), and repeated administration of a cannabinoid agonist produces behavioral 
sensitization and cross-sensitization to morphine (Cadoni et al., 2001, 2008). Co-
administration of a cannabinoid agonist with morphine enhanced sensitization to 
morphine-induced locomotor activity, and pre-exposure to a cannabinoid agonist 
increases morphine self-administration (Norwood et al., 2003). Morphine conditioned 
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place preference is also enhanced by pretreatment with a CB1 agonist (Manzanedo et al., 
2004), as is the reinforcing efficacy of other opioids such as heroin (Solinas et al., 2005). 
These data suggest that CB1 agonists and opioids interact in a similar manner across a 
variety of behavioral endpoints. 
 Findings such as those discussed above have prompted researchers to examine the 
role of endogenous cannabinoids in the effects of opioids, and recent findings suggest 
that manipulations of endogenous cannabinoid activity at CB1 receptors have functional 
consequences on the behavioral effects of opioids. For instance, a selective CB1 
antagonist but not a CB2 antagonist blocks morphine-induced antinociception as 
measured by an inflammatory pain model (Pacheco et al., 2008) and the thermal tail-flick 
test (Pacheco et al., 2009) in mice. In addition, there is emerging evidence that inhibition 
of the degradation of AEA might enhance the antinociceptive effects of morphine 
(Pacheco et al., 2008, 2009; Haller et al., 2008). Interestingly, whereas direct CB1 
agonism results in hypothermia, catalepsy, decreases in locomotor activity (Adams et al., 
1998) and enhances the reinforcing effects of opioids (Solinas et al., 2005), the disruption 
of AEA breakdown by FAAH does not (Cravatt et al., 2001; Lichtman et al., 2004, 2004; 
Solinas et al., 2005; Moore et al., 2005). Thus, the consequences of pharmacological 
enhancement of AEA activity on morphine’s behavioral effects might be determined by 
the behavioral endpoint that is used to examine this interaction. 
 As discussed above, studies using pharmacological manipulations of endogenous 
cannabinoid activity have provided evidence that suggests that endogenous cannabinoids 
modulate morphine’s antinociceptive effects; however the results of studies using genetic 
manipulations of cannabinoid activity are in conflict with these findings. Specifically, 
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CB1 knockout mice do not differ from their wild-type littermates with regard to 
morphine’s antinociceptive effects (Ledent et al., 1999; Valverde et al., 2000). On their 
own, these findings suggest that activity at CB1 is not integral to the antinociceptive 
effects of morphine. Interestingly, studies using knockout mice have implicated CB1 
receptors in morphine’s reinforcing (Cossu et al., 2001) and conditioned effects (Martin 
et al., 2000) again suggesting that the behavioral endpoint used to study these 
interactions, but also the manner of manipulating cannabinoid signaling, could be a 
determinant of the role of CB1 activity in the effects of opioids. 
 Based on such findings, it is important to further clarify the role of endogenous 
cannabinoid activity in the behavioral effects of morphine. Therefore, the proposed 
experiments examine the consequences of inhibition and potentiation of endogenous 
cannabinoid signaling on the effects of morphine. This will be accomplished by using 
genetic and pharmacological manipulations in combination with behavioral assays that 
are designed to assess the degree to which these manipulations produce antinociception 
and affect other behaviors. 
 
Preclinical Assessment of Antinociception 
 There are ongoing discussions of the nature of pain research and how researchers 
can evaluate pain and potential therapeutics in more valid ways (Mogil and Crager, 2004, 
2005; Vierck et al., 2005; Negus et al., 2006). Among the major concerns is how to 
minimize inconsistencies between promising results in basic research and the failure of 
those results to translate to the clinical setting. A strategy aimed at accomplishing this is 
the development of new preclinical models. Many traditional preclinical pain models rely 
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on noxious stimulus-induced behaviors as the dependent variable. An example of this is 
the hotplate assay where the subject, typically a mouse or rat, is placed onto a hot surface 
and the latency to make a response (e.g. licking of the hind paw or jumping) is used as 
the dependent variable. If an intervention (e.g. a candidate antinociceptive drug) produces 
an increase in the latency to perform the response, this may be interpreted as an 
antinociceptive effect; however, a potential problem with such an interpretation is that, in 
such models, an intervention that produces sedation or motor impairment may result in 
effects that are mistaken as antinociception. Researchers are aware of such issues and 
have attempted to address them by assessing the effects of candidate interventions on 
other behaviors such as locomotor activity, rotorod performance, and behavior 
maintained under schedules of reinforcement. Recently, researchers have proposed that 
models that measure pain-suppressed behaviors might complement assays of pain-elicited 
behavior. For instance, Stevenson et al. (2006) found that morphine and the 
antipsychotic, haloperidol, which is known to alter locomotor activity in rodents, 
decreases acetic acid-induced writhing (a pain-elicited behavior). However, only 
morphine inhibited acetic acid-suppressed feeding (a pain-suppressed behavior). 
Therefore, morphine, a known analgesic produced antinociception as defined by both 
assays, whereas the suppression of writhing produced by haloperidol may have been the 
result of nonspecific effects such as motor impairment or other effects that influenced the 
animals’ ability to produce the measured response.  
 This is a consideration that is very relevant to the current topic. As discussed 
above, opioid and cannabinoid agonists produce effects such as sedation and disruption 
of motor activity (Gühring et al., 2001; Pascual et al., 2005; Smith et al., 2009) in 
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addition to their antinociceptive effects, and these effects could be a source of confounds 
in studies utilizing pain-elicited behaviors alone. Assays measuring pain-suppressed 
behavior are relatively novel and their utility has not been fully determined, but they may 
be very useful in attempting to separate the antinociceptive effects of cannabinoids, 
opioids, and their combination, from nonspecific effects such as motor impairment. 
 Researchers studying the antinociceptive effects of drugs often use models that 
examine other behavioral endpoints in concert with preclinical pain assays. One reason 
for this, as discussed above, is to try to account for possible confounds; however, there is 
another important rationale for this approach. Numerous studies, including some from 
our own laboratory, have indicated that behavioral endpoint is an important determinant 
of the effects of drugs and drug combinations (Stevenson et al., 2003, 2005; Fischer and 
Dykstra, 2006; Fischer et al., 2008b). Therefore, it is important to study the interactions 
of the cannabinoid and opioid systems across a variety of behavioral endpoints. 
 
Goals of the Dissertation 
 The primary goal of this project is to examine the role of the endogenous 
cannabinoid system in mediating the antinociceptive and other behavioral effects of 
morphine. A secondary goal is to assess the utility of preclinical pain models that 
measure pain-suppressed behaviors as the dependent variable. The experiments described 
here aim to achieve these goals by addressing three specific aims. Specific Aim 1 will 
utilize CB1 receptor knockout mice to determine the consequences of constitutive CB1 
inactivity on the effects of morphine in two models of pain-elicited behavior (the hotplate 
assay and the acetic acid-induced writhing assay) and two models of pain-suppressed 
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behavior (acetic acid-suppressed feeding and wheel running). Aim 2 will use assays of 
pain-elicited behavior to determine if pharmacological inhibition of FAAH or inhibition 
of AEA reuptake produces antinociception and enhances the antinociceptive effects of 
morphine in a manner that is comparable to direct CB1 agonism. Aim 3 will determine 
the consequences of pharmacological inhibition of FAAH and AEA reuptake, alone and 
in combination with morphine, in assays of pain-suppressed behavior and an assay of 
schedule controlled behavior. Together, these experiments will extend our knowledge of 
the role of the endogenous cannabinoid system in the antinociceptive effects of morphine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 2 
 
EXPERIMENT 1: Effects of Morphine on Pain-elicited and Pain-suppressed 
Behavior in CB1 Knockout and Wildtype Mice 
ABSTRACT 
Rationale Pharmacological manipulations of the type 1 cannabinoid receptor (CB1) 
suggest a role for CB1 in morphine-induced antinociception, but studies utilizing CB1 
knockout (KO) mice do not support this conclusion. Since studies using CB1 KO mice to 
study morphine’s antinociceptive effects have only examined thermal pain models, the 
current study examines these interactions in models that employ a chemical stimulus. 
Objectives To determine whether the findings obtained with thermal pain models extend 
to models that use a chemical stimulus, the effects of morphine on acetic acid-induced 
writhing were examined in CB1 KO and wildtype (WT) mice. In addition, behaviors that 
decrease in response to acetic acid injection (pain-suppressed behaviors), feeding and 
wheel-running, were examined. Investigations were also carried out in the hotplate assay. 
Finally, the CB1 antagonist SR141716A was used to determine if there are dissimilar 
consequences of constitutive and acute inactivity of CB1 on morphine antinociception in 
these assays.  
Results Morphine attenuated acetic acid-induced writhing, and responding in the hotplate 
assay. Morphine also attenuated the suppression of wheel-running following an injection 
of acetic acid, but did not block the suppression of feeding. Although morphine’s effects 
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were not altered in CB1 KO mice, SR141716A attenuated the effects of morphine in 
C57BL/6 mice. 
Conclusions The antinociceptive effects of morphine do not differ in CB1 KO and WT 
mice in preclinical pain models using both thermal and chemical stimuli. Since 
SR141716A did attenuate the effects of morphine it is possible that CB1 KO undergo 
developmental changes that mask the role of CB1 in morphine’s antinociceptive effects. 
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INTRODUCTION 
 The cannabinoid and opioid systems include G-protein-coupled receptors, type 1 
cannabinoid (CB1) and-opioid receptors, respectively, that have parallel distribution 
throughout the CNS. The activation of these receptors can produce similar effects such as 
decreased cyclic AMP and inhibition of synaptic activity (Waldhoer et al., 2004; Pertwee, 
2006). Further, agonists of CB1 receptors and -opioid receptors produce similar 
behavioral effects that include antinociception (Cox and Welch, 2004), alterations of 
locomotor activity (Pascual et al., 2005; Smith et al., 2009), food consumption (Järbe and 
DiPatrizio, 2005; Li et al., 2006), and thermoregulation (Wang et al., 2008; Diaz et al., 
2009). Moreover, agonists at these receptors serve as reinforcers in self-administration 
paradigms (Negus and Rice, 2008; Justinova et al., 2008).  
 Numerous studies have examined the interactions of these systems, and 
antinociception is one area in which interactions have been consistently reported. The 
cannabinoid agonist delta-9-tetrahydrocannabinol (9-THC) potentiates the effects of 
morphine in the mouse tail-flick test (Cichewicz and McCarthy, 2003) and the rat paw 
pressure test (Cox et al., 2007). There is also evidence that endogenous cannabinoids 
modulate the effects of opioids. The CB1 antagonist AM251 blocks morphine-induced 
antinociception as measured by an inflammatory pain model (Pacheco et al., 2008) and 
the tail-flick test in mice (Pacheco et al., 2009). Methylarachidonoylflurophosphate 
(MAFP), which inhibits the degradation of the endogenous cannabinoids anandamide 
(AEA), and 2-arachidonoylethanolamine (2-AG), enhances the effects of morphine 
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(Pacheco et al., 2009), as does administration of AEA in combination with the fatty acid 
amide hydrolase (FAAH) inhibitor URB597 (Haller et al., 2008). 
 Although studies utilizing pharmacological manipulations of cannabinoid 
signaling suggest a role for endogenous cannabinoids in the antinociceptive effects of 
opioids, the results of research with genetic models do not. Specifically, morphine is 
equally effective in CB1 knockout (KO) and wildtype (WT) mice in the hotplate and tail 
immersion assays (Ledent et al., 1999; Valverde et al., 2000). It is noteworthy that a 
variety of pain models have been used in studies utilizing pharmacological manipulations 
to examine cannabinoid-opioid interactions (Cox et al., 2007; Pacheco et al., 2008, 2009) 
and in studies phenotyping CB1 KO mice (Ledent et al., 1999; Zimmer et al., 1999). In 
contrast, studies assessing the antinociceptive effects of morphine in CB1 knockout mice 
have only examined behaviors that occur in response to acute presentation of thermal 
noxious stimuli (Ledent et al., 1999; Valverde et al., 2000). 
 The mechanisms underlying nociception and antinociception depend on factors 
such as the modality and duration of noxious stimuli (Mogil, 2009) as well as the 
behavioral endpoints that are used to measure the pain response (Le Bars et al., 2001). 
This being the case, the current studies extend the existing research on interactions 
between the cannabinoid and opioid systems by examining CB1 KO and WT mice in 
preclinical tonic pain assays that employ chemical noxious stimuli and measure 
behavioral responses that either decrease or increase in response to exposure to noxious 
stimuli. Specifically, we examined the effects of morphine on the behavioral 
consequences of intraperitoneal injection of acetic acid in CB1 KO and WT mice. We 
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sought to determine the role of the CB1 receptor in the effects of morphine on the 
writhing response to acetic acid injection, and on behaviors that decrease in response to 
acetic acid injection, namely feeding and wheel-running (pain-suppressed behaviors). 
CB1 KO and WT were also used to determine the effects of morphine in a thermal 
(hotplate) assay for comparison.  
 In addition to noxious stimulus modality and duration, another variable that might 
account for the dissimilar results obtained from studies using CB1 KO mice and 
antagonists to examine the antinociceptive effects of morphine is that constitutive 
inactivity of CB1 in the KO animals might produce changes that mask the role of this 
receptor in the effects of morphine. Accordingly, SR141716A, a CB1 antagonist, was 
used to determine the effects of acute disruption of CB1 activity on morphine 
antinociception.  
METHODS 
Subjects 
 Male and female CB1 KO mice and age-matched WT littermates were used for 
these experiments (total animal numbers: female KO = 49, male KO = 52, female WT = 
51, and male WT = 51). The distribution of males and females was balanced across 
groups except in instances where there were an odd number of mice, in which case males 
outnumbered females by 1. Mice were generated on a full C57BL/6 background (Zimmer 
et al. 1999) and heterozygous breeding pairs were obtained from Virginia 
Commonwealth University. Due to limited access to CB1 KO and WT mice, male 
C57BL/6 mice were used in studies examining morphine in combination with 
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SR141716A. All mice were bred and housed in the animal facilities of the Department of 
Psychology at the University of North Carolina at Chapel Hill. Mice were group housed 
after weaning and were subsequently individually housed where specified by the 
experimental protocols. Average mouse weights at the time of testing were as follows: 
female KO = 19.89 g, male KO = 24.09 g, female WT = 21.42 g and male WT = 26.73 g. 
C57BL/6 mice weighed 27.83 g on average 
 Mice had free access to food and water except where specified by the 
experimental protocols below. Lights were programmed on a 12 h light/dark cycle with 
lights off at 7:00am. All experiments took place during the dark cycle. Animal protocols 
were approved by the institutional animal care and use committee, and the methods were 
in accord with the “Guide for the Care and Use of Laboratory Animals” (Institute of 
Laboratory Animal Resources, Commission on Life Sciences, National Research 
Council, 1996) 
Experimental Procedures 
Assays of pain-elicited behavior 
Hotplate 
 Mice were group housed and had free access to food and water for these 
experiments. Prior to testing, mice were habituated to the testing room and handling for 
two days. On the test day, antinociception was assessed using a hotplate analgesia meter 
(25.3 X 25.3 cm; Columbus Instruments, Columbus, OH). During the hotplate assay the 
mouse was placed onto the surface of the apparatus and the latency to lick or flutter the 
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hind paws, or to jump from the hotplate surface was recorded. Responses were measured 
to the nearest 0.1 s and predetermined cutoff time of 20 s was defined as the maximum 
trial duration in order to prevent tissue damage. Immediately following termination of a 
trial, whether due to an animal’s response or the fact that the cutoff time elapsed, mice 
were removed from the apparatus and returned to the home cage.  
 Baseline latencies were assessed in CB1 KO and WT mice (n = 12 of each 
genotype) across a range of hotplate temperatures (44-56±0.1°C). Temperatures were 
tested in ascending order and 15 m elapsed between trials. One week later the same mice 
were used to assess the effects of morphine using a hotplate temperature of 56±0.1°C. 
Responses were measured 30 and 15 m prior to drug administration and the latencies 
from these trials were averaged to yield one baseline value. During dose-effect 
determination, cumulative doses of morphine were administered 30 m apart in half log 
increments. Temperatures and doses were examined in a repeated measures fashion. The 
effect of each dose of morphine is expressed as the percentage of the maximum possible 
effect (%MPE): [postdrug latency (s) – baseline latency (s)] / [20 – baseline latency (s)]. 
 To determine the consequences of pretreatment with the CB1 antagonist 
SR141716A on morphine antinociception, C57BL/6 mice were tested at 56
o
 as described 
above. Morphine (32.0 mg/kg) and SR141716A (3.0 mg/kg) were administered alone and 
in combination 30 and 60 m prior to testing, respectively. These doses were selected 
based on prior work in our laboratory with these compounds in this mouse strain. 
Acetic acid-induced writhing 
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 Mice were group housed and had free access to food and water until 12 and 5 h 
prior to testing, respectively. Mice were habituated to the testing room and handling for 
two days prior to testing. In addition, mice were given a 30 m session with free access to 
32% liquid nutrition (Vanilla flavor, CVS brand) on the day prior to testing. Food and 
water deprivation and access to liquid nutrition occurred due to the fact that data for 
acetic acid-suppressed feeding were collected in these animals during the same session 
(see below). 
 On the test day, separate groups of mice were injected with saline or morphine 
(0.1 – 10.0 mg/kg) 45 m prior to the start of the test session (n = 5-6 of each genotype per 
group). Immediately prior to the test session, mice were injected with saline or 0.56% 
acetic acid. Following the second injection, mice were immediately placed into clean 
polycarbonate mouse cages (11.5” X 7.5” X 5”; Allentown Inc, Allentown, NJ) 
containing dishes of 32% liquid nutrition, and their behavior was videotaped for 30 m. 
Following the session, the tapes were viewed and the number of writhes was recorded. 
Writhes were operationally defined as an elongation of the body with simultaneous 
extension of the hind limbs. The effect of each dose of morphine is expressed as percent 
inhibition of writhing (% Inhibition): [((writhes in saline treated mice - writhes in drug 
treated mice) / writhes in saline treated mice) X 100]. 
 To determine the consequences of pretreatment with the CB1 antagonist 
SR141716A on morphine antinociception in the writhing assay, C57BL/6 mice were 
tested as described above. Morphine (3.2 mg/kg) and SR141716A (3.0 mg/kg) were 
administered alone and in combination 45 and 60 m prior to testing, respectively. These 
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doses were selected based on prior work in our laboratory with these compounds in this 
mouse strain. 
Assays of pain-suppressed behavior 
Acetic acid-suppressed feeding 
 Mice were group housed and had free access to food and water until 12 and 5 h 
prior to testing, respectively. Mice were habituated to the testing room and handling for 
two days prior to testing. In addition, 24 h prior to testing, mice were given a 30 m 
session of free access to approximately 14 ml of 32% liquid nutrition (Vanilla flavor, 
CVS brand; composition as used: protein = 0.36 g/oz, carbohydrate = 1.6 g/oz, and fat = 
0.24 g/oz) in order to reduce the novelty of the substance. During this session, individual 
mice were placed into bedding-free polycarbonate mouse cages (11.5” X 7.5” X 5”; 
Allentown Inc, Allentown, NJ) that contained a glass dish containing liquid nutrition and 
were allowed to explore the testing environment and consume the liquid nutrition.  
 On the test day, separate groups of mice were injected with saline or morphine 
(0.1 – 10.0 mg/kg) 45 m prior to the start of the test session (n = 5-6 of each genotype per 
group). Immediately prior to the test session, mice were injected with 0.56% acetic acid 
or saline. Following the second injection mice were immediately placed into clean 
polycarbonate mouse cages (11.5” X 7.5” X 5”; Allentown Inc, Allentown, NJ) 
containing liquid nutrition and the amount of liquid consumed was measured for 30 m. 
Consumption was quantified by subtracting the weight of the liquid-containing dishes 
after the session from the weight obtained prior to the session. Because body size might 
influence consumption independent of other variables, this value was divided by the 
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animals’ weight (grams of liquid consumed per gram of body weight). In the event of 
spillage, the data were discarded. The effect of each dose of morphine on pain-suppressed 
consumption is expressed as percent of non-suppressed consumption (% Control): 
[(acetic acid-suppressed consumption (g/g) / non-suppressed consumption (g/g)) X 100]. 
 To determine the consequences of pretreatment with the CB1 antagonist 
SR141716A on morphine antinociception in the pain-suppressed feeding assay, C57BL/6 
mice were tested as described above. Morphine (3.2 mg/kg) and SR141716A (3.0 mg/kg) 
were administered alone and in combination 45 and 60 m prior to testing, respectively. 
The effects of 3.0 mg/kg SR141716A on non-suppressed feeding were also determined. 
These doses were selected based on prior work in our laboratory with these compounds in 
this mouse strain. 
Acetic acid-suppressed wheel-running 
 Mice were grouped housed in standard polycarbonate mouse cages (11.5” X 7.5” 
X 5”; Allentown Inc, Allentown, NJ) until the start of these experiments. At this time 
mice were individually housed in polycarbonate cages (14” X 10.5” X 5.5”; Tecniplast 
USA Inc., Exton, PA) containing running wheels (ENV-044, Med Associates, St. Albans, 
VT). Testing occurred after three weeks of habituation to handling and acquisition of 
wheel-running behavior. On the day prior to testing (control session) mice were injected 
with saline followed 45 m later by a second injection of saline. The next day (test 
session), 24 h after the control session, separate groups of mice were injected with 
morphine (0.32 – 3.2 mg/kg) or saline and 45 m later were injected with 0.56% acetic 
acid or saline (n = 6-7 of each genotype per group). Wheel-running was recorded for 30 
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m following the second injection (acetic acid or saline) during the control and test 
sessions. The effect of each dose of morphine on pain-suppressed wheel-running is 
expressed as percent of non-suppressed wheel-running (% Control): [(acetic acid-
suppressed running / non-suppressed running) X 100]. 
 To determine the consequences of pretreatment with the CB1 antagonist 
SR141716A on morphine antinociception in the pain-suppressed wheel-running assay, 
C57BL/6 mice were tested as described above. Morphine (1.0 mg/kg) and SR141716A 
(3.0 mg/kg) were administered alone and in combination 45 and 60 m prior to testing, 
respectively. The effects of morphine and SR141716A on non-suppressed running were 
also determined. These doses were selected based on prior work in our laboratory with 
these compounds in this mouse strain. 
Drugs 
 Morphine sulphate and SR141716A were provided by the National Institute on 
Drug Abuse (Bethesda, MD, USA). Morphine was dissolved in 0.9% saline and 
SR141716A was dissolved in a vehicle of 100% ethanol, Alkamuls EL-620 (Rhodia, 
Cranbury, New Jersey) and saline in a ratio of 1:1:18. Acetic acid was purchased from 
Fischer Scientific and diluted in 0.9% saline. Morphine and SR141716A were injected 
subcutaneously and acetic acid was injected intraperitoneally at a volume of 0.1 ml/10 g. 
Data Analysis 
 No sex differences were detected in these studies and all data analyses that follow 
were conducted with groups collapsed across this variable. Data are presented as raw 
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values (±SEM) or expressed as mean (±SEM) % MPE, % Inhibition, or % Control 
depending on the assay (see above). The morphine dose required to produce a 50% 
maximal effect (ED50) was derived using log-linear interpolation when possible, and 
differences in morphine potency between genotypes were determined and expressed as a 
potency ratio with 95% confidence limits. Two-factor analyses of variance (ANOVA) 
were performed to determine the effects of genotype and dose. Student’s t-test were used 
when appropriate to determine genotypic differences and the effects of SR141716A 
under control conditions. In studies examining the effects of pretreatment with 
SR141716A on morphine antinociception, one-way ANOVA with Bonferoni 
comparisons were used to determine treatment effects. All statistical analyses were 
conducted with an alpha level of significance set at p < 0.05. 
RESULTS 
 Fig. 2.1 (top) shows the response latencies for CB1 KO and WT mice across a 
range of temperatures (44-56±0.1°C) on the hotplate. Two-factor ANOVA revealed 
temperature dependent decreases in response latencies [F(4,110) = 296.66, p < 0.05]. 
However, there were no genotypic differences in response latencies and there was no 
interaction between genotype and temperature. Baseline responses at 56
 o
 did not differ 
between assessments during the temperature effect curve or morphine dose-effect curve. 
Morphine (Fig. 2.1 bottom) produced dose-dependent antinociception on the 56
o
 hotplate 
[F(3,66) = 174.18, p < 0.05] in CB1 KO [ED50 (95% CL) = 7.35 (5.99-9.01)] and WT 
mice [ED50 (95% CL) = 8.37 (6.97-10.05)] but there were no differences in the effects of 
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morphine between genotypes [potency ratio = 1.11 (0.85-1.45)], and no significant 
interaction of morphine and genotype. 
 Fig. 2.2 shows the effects of morphine (32.0 mg/kg) and SR141716A (3.0 mg/kg) 
alone and in combination in the hotplate assay at 56
o
. One-way ANOVA revealed a 
significant effect of treatment [F(3,32) = 111.02, p < 0.05] and bonferoni comparisons 
show that SR141716A had no effect on hotplate latency. Morphine produced a 100% 
maximum possible effect in all animals tested (p < .05 vs saline) whereas pretreatment 
with SR141716A significantly attenuated the effects of morphine (p < .05 vs morphine 
alone), though there was still a significant antinociceptive effect (p < .05 vs saline). 
 Fig. 2.3 (top) shows the number of writhes produced by acetic acid in CB1 KO 
and WT mice in the absence of morphine. KO mice writhed significantly more [28±4.1] 
than WT mice [15±4.1] in response to acetic acid [t(10) = 2.2, p < 0.05]. The raw data 
(number of writhes; Fig. 2.3 bottom inset) indicate that these genotypic differences 
persisted when morphine was administered prior to acetic acid [F(1,50) = 16.47, p < 
0.05]. However, when basal genotypic differences were taken into account by expressing 
the data as percent inhibition of writhing (Fig. 2.3 bottom), morphine dose-dependently 
inhibited writhing [F(4,50) = 28.99, p < 0.05] in CB1 KO [ED50 (95% CL) = 0.37 (0.27-
0.51)] and WT mice [ED50 (95% CL) = 0.34 (0.17-0.66)] and there were no differences 
in the effects of morphine between genotypes [potency ratio = 1.13 (0.61-2.13)]; there 
was no significant interaction of genotype and dose. 
 Fig. 2.4 shows the effects of 3.2 mg/kg morphine and 3.0 mg/kg SR141716A, 
alone in and in combination on acetic acid induced writhing. One-way ANOVA revealed 
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a significant effect of treatment [F(3.20) = 23.90, p < 0.05] such that SR141716 produced 
a slight but non-significant increase in writhes. Morphine significantly inhibited writhing 
(p < .05 vs saline) and this effect was attenuated by pretreatment with SR141716A (p < 
0.05 vs saline). 
 Fig. 2.5 (top) shows the effects of saline and 1.0 mg/kg morphine on liquid 
nutrition consumption in CB1 KO and WT in the absence of acetic acid. There was a 
main effect of genotype [F(1,21) = 9.16, p < 0.05] where WT mice consumed more liquid 
nutrition than KO mice, but 1.0 mg/kg morphine had no effect on non-suppressed feeding 
and there was not a significant interaction between genotype and treatment. 
Intraperitoneal injection of acetic acid almost completely suppressed consumption in both 
genotypes [WT: 0.008±0.002 g/g; KO: 0.007±0.001 g/g]. Morphine (Fig. 2.5 bottom) 
was not effective at attenuating acetic acid-induced suppression of consumption. Table 
2.1 shows raw consumption data for each genotype (unadjusted by weight). 
 Pretreatment with 3.0 mg/kg SR141716A (Fig. 2.6 (top)) decreased consumption 
of ensure in the absence of acetic acid (i.e. consumption not suppressed by pain; t (5,5) = 
2.38, p < .05). Figure 2.6 (bottom) shows that neither 3.2 mg/kg morphine nor 3.0 mg/kg 
SR141716A, alone or in combination, altered consumption that was suppressed by acetic 
acid injection. 
 Fig. 2.7 (top) shows the effects of saline and 3.2 mg/kg morphine on wheel-
running behavior in CB1 KO and WT mice in the absence of acetic acid. There was a 
main effect of genotype [F(1,20) = 9.36, p < 0.05] where WT mice displayed higher 
levels of wheel-running than KO mice, however 3.2 mg/kg morphine had no effect on 
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non-suppressed wheel-running and there was no significant interaction between genotype 
and treatment. Fig. 2.7 (bottom inset) shows that intraperitoneal injection of acetic acid 
completely suppressed wheel-running in both genotypes. Morphine significantly 
attenuated the suppression of wheel-running by injection of acetic acid [F(4,53) = 6.03, p 
< 0.05] and the genotypic differences seen with non-suppressed wheel-running persisted 
with WT mice displaying higher levels of wheel-running than KO mice [F(1,53) = 5.10, p 
< 0.05]; there was no significant interaction of morphine and genotype. When basal 
genotypic differences in wheel-running were taken into account by expressing wheel-
running as percentage of control running, the effects of morphine on acetic acid-
suppressed wheel running did not differ between genotypes. Morphine ED50 (95% CL) = 
1.72 (0.77-3.79) for KO mice and 1.38 (0.84-2.25) for WT mice [potency ratio = 1.18 
(0.51-2.94)]. 
 Fig. 2.8 (top) shows that when administered in the absence of acetic acid, 
morphine and SR141716A, alone and in combination do not alter wheel running behavior 
in C57BL/6 mice. The bottom portion of Fig. 2.8 shows the effects of morphine, alone 
and in combination with SR141716A, on pain-suppressed wheel running. One-way 
ANOVA revealed a significant effect of treatment [F(2,19) = 10.44, p < 0.05], such that 
mice treated with morphine produced significantly more wheel revolutions than mice 
treated with saline (p < .05 vs saline). Pretreatment with SR141716A blocked this effect 
(p < 0.5 vs morphine alone). 
DISCUSSION 
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 The primary goal of these experiments was to investigate the role of the CB1 
receptor in the antinociceptive effects of morphine in CB1 KO mice. Previous studies 
have shown that CB1 KO mice do not respond differently than WT mice in models of 
acute thermal pain. In the present study, we extended these findings by determining the 
effects of morphine in CB1 KO and WT mice in models examining pain resulting from 
i.p. injection of acetic acid. These models allow for the assessment of both pain-elicited 
behaviors (writhing) and pain-suppressed behaviors (food consumption and wheel-
running). In addition, we compared the results seen in CB1 KO and WT mice with results 
obtained with the CB1 antagonist, SR141716A in C57BL/6 mice. 
The two genotypes did not differ in their responses on the hotplate across 
temperatures that ranged from innocuous to noxious (44-56±0.1°C). This suggests that 
CB1 receptors are not integral to this behavioral response to thermal noxious stimuli. 
Previous research has revealed mixed results with regard to nociceptive responding in the 
hotplate assay between CB1 KO and WT mice. In a study utilizing mice on the same 
background as used in the present study (C57BL/6), CB1 KO mice were found to have 
increased latencies (interpreted as hypoalgesia) relative to WT mice (Zimmer et al., 
1999). Consistent with the data obtained in the present study, studies utilizing mice on a 
CD1 background showed no differences between genotypes (Ledent et al., 1999; 
Valverde et al., 2000).  
Previous studies have obtained mixed results when examining the effects of CB1 
antagonists on responses to acute thermal pain with some studies revealing no effect 
(Cravatt et al., 2001; Hough et al., 2002) and others suggesting a hyperalgesic effect 
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(Richardson et al., 1998). The present findings are consistent with the former in that, at 
the dose tested, SR141716A did not alter hotplate latencies. 
That there were no differences between CB1 KO and WT mice in response to 
morphine in the hotplate assay suggests that the absence of functioning CB1 receptors 
does not alter the effects of morphine in this context. Pretreatment with SR141716A, 
however, did produce a modest but significant attenuation of the antinociceptive effects 
of morphine in the hotplate assay. This finding is consistent with other data that suggest 
that CB1 receptors do modulate the effects of morphine (Pacheco et al., 2008, 2009). 
Taken together, these findings suggest that morphine’s effects do not differ in WT and 
KO mice because of developmental changes that have taken place in these mice. 
In order to determine if the findings of studies using acute thermal pain extend to 
other stimulus modalities and durations, experiments were conducted with acetic acid 
serving as a tonic, chemical noxious stimulus. Acetic acid (0.56%) produced more 
writhes in CB1 KO mice than in CB1 WT mice, suggesting a role for CB1 receptors in 
the writhing response to acetic acid. Other findings also suggest a role for CB1 receptors 
in responses to chemical noxious stimuli. For instance, disruption of FAAH activity by 
pharmacological or genetic means inhibits acetic acid-induced writhing (Naidu et al., 
2010), and inhibition of CB1 signaling results in hyperalgesia in the formalin test 
(Calignano et al., 1998). On the other hand, studies utilizing CB1 KO and WT mice on a 
CD1 background (Ledent et al., 1999; Valverde et al., 2000) found no differences 
between genotypes in the writhing test. At the dose tested in the present experiments, the 
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CB1 antagonist SR141716A did not alter the number of writhes elicited by acetic acid 
which is consistent with other findings (Booker et al., 2009). 
Morphine dose-dependently decreased the number of writhes that result from 
intraperitoneal injection of acetic acid, and there were no genotypic differences in the 
effects of morphine in this assay. This suggests that results obtained in other studies 
utilizing acute thermal pain to study the antinociceptive effects of morphine in CB1 
knockout mice extend to this commonly used model of tonic pain. On the other hand, 
pretreatment with SR141716A attenuated the ability of morphine to inhibit the writhing 
response, again suggesting that morphine’s effects are modulated by CB1, but this role is 
masked in CB1 knockout mice. 
Nociception elicits pain-related behaviors and suppresses other behaviors. 
Research has demonstrated the utility of preclinical pain assays that measure pain-
suppressed behavior in addition to traditional assays that measure pain-elicited behavior 
(Martin et al., 2005; Stevenson et al., 2006, 2009; Matson et al., 2007; Pereira Do Carmo 
et al., 2009; Negus et al., 2010). Consequently, the present studies also used CB1 KO and 
WT mice to determine the role of the endogenous cannabinoid system in morphine’s 
effects on behaviors that are suppressed by exposure to noxious stimuli. 
Consumption of palatable food, a behavior that occurs at a high rate under control 
conditions, is decreased upon exposure to noxious stimuli (Stevenson et al., 2006). In the 
present studies, control consumption was decreased in mice lacking CB1. This finding, 
along with the finding that SR141716A decreased non-suppressed food consumption is 
consistent with a growing literature indicating that the cannabinoid system is an 
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important mediator of feeding behaviors. Other studies assessing feeding behavior in 
CB1 KO mice have revealed results similar to those found here (Cota et al., 2003). 
Moreover, it has been shown that CB1 agonists and antagonists produce hyperphagia 
(Miller et al., 2004) and hypophagia (Ward et al., 2009), respectively. 
In contrast to findings obtained from studies utilizing C57BL/6J mice (Stevenson 
et al., 2006), in the current study morphine was not effective at attenuating the 
suppression of feeding by i.p. injections of acetic acid. It seems unlikely that this result is 
due to suppression of consumption by morphine as morphine had no effect on non-
suppressed consumption. The reasons for the discrepancies between the present studies 
and the Stevenson et al. study are unclear, but there were numerous differences in 
experimental parameters between the two studies (e.g. amount of exposure to acetic acid 
and food) that might contribute to the dissimilar findings.  
Wheel-running also occurs at a high rate in rodents, and is susceptible to 
suppression by noxious stimuli. Under baseline conditions, CB1 KO mice exhibited less 
wheel-running behavior than WT mice which is consistent with other findings (Dubreucq 
et al., 2010). The CB1 antagonist CB1 antagonist, SR141716A, did not reduce wheel-
running when administered to C57BL/6 mice though it has been shown to do so in rats 
(Keeney et al., 2008). The findings in CB1 KO mice might suggest a role of the 
endocannabinoid system in the reinforcing effects of wheel-running, but it might also be 
the case that the differences seen in the present studies are related to other effects of CB1 
knockout. For instance, the decreased caloric intake by CB1 KO mice, demonstrated by 
  
30 
 
others (Cota et al., 2003) and suggested by the present feeding experiments, might lead to 
decreased wheel-running behavior. 
Unlike the results observed in the pain-suppressed feeding assay, morphine dose-
dependently attenuated the suppression of wheel-running behavior after i.p. injection of 
acetic acid. These findings are consistent with previous reports showing that opioids are 
effective at blocking decreases in a variety of behaviors that result from exposure to 
noxious stimuli (Martin et al., 2005; Stevenson et al., 2006, 2009; Matson et al., 2007; 
Pereira Do Carmo et al., 2009; Negus et al., 2010). This suggests that under these 
conditions, morphine reduces nociception in a manner that not only decreases reflexive 
responses to i.p. injection of acetic acid (i.e. writhing), but restores rates of pain-
suppressed spontaneous behavior. In addition, 3.2 mg/kg morphine, which produced the 
peak effect on pain-suppressed wheel-running in CB1 KO and WT mice, had no effect on 
non-suppressed wheel-running. This suggests that the present results are not due to non-
specific increases in wheel-running as a result of morphine administration. As stated 
above, there were no genotypic differences in the effects of morphine on suppressed or 
non-suppressed wheel-running. On the other hand, as was the case in the other models 
used here, SR141716A significantly attenuated the ability of morphine to block the 
suppression of wheel-running by acetic acid injection, again suggesting a role for CB1 
receptors in the antinociceptive effects of morphine in this assay. 
The findings of the present studies are consistent with research demonstrating that 
CB1 KO and WT mice do not respond differently to morphine on endpoints related to 
antinociception (Ledent et al., 1999; Valverde et al., 2000). Moreover, the findings with 
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SR141716A are consistent with other studies that demonstrate a reduction of the 
antinociceptive effects of morphine upon administration of CB1 antagonists (Pacheco et 
al., 2008, 2009). Combined administration of anandamide and a selective inhibitor of its 
degradation enhanced the effects of morphine (Haller et al., 2008), and Pacheco et al. 
(2009) also showed that MAFP, which non-selectively inhibits the catabolism of AEA 
and 2-AG, enhanced the effects of morphine. These authors also demonstrated that a CB2 
antagonist did not alter the effects of morphine and it has been demonstrated that the 
effects of MAFP are mediated via CB1 (Ates et al., 2003).  
In the context of the literature, the present results showing attenuation of 
morphine’s effects by the CB1 antagonist, SR141716A, suggest that endogenous 
cannabinoids are involved in the antinociceptive effects of morphine in models of acute 
thermal pain and chemical pain. The finding that morphine-induced antinociception does 
not differ in CB1 KO and WT mice indicates that the constitutive absence of CB1 
signaling may result in compensatory changes that mask this role.  
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Table 2.1 Effects of morphine on liquid nutrition consumption (ml) 
 
 
Treatment KO WT 
Control 1.26 (0.18) 2.05 (0.01) 
Saline 0.15 (0.02) 0.22 (0.05) 
  0.1 mg/kg 0.25 (0.03) 0.22 (0.05) 
  0.32 mg/kg 0.18 (0.02) 0.25 (0.03) 
  1.0 mg/kg 0.15 (0.02) 0.47 (0.23) 
  3.2 mg/kg 0.26 (0.03) 0.58 (0.32) 
10.0 mg/kg 0.17 (0.02) 0.23 (0.03) 
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Fig. 2.1 Hotplate assay for CB1 KO and WT mice. Top, temperature-effect curves (44-56 
o
C) in the absence of morphine. Abscissa: hotplate temperature (
o
C). Ordinate: mean 
response latency in seconds. Bottom, morphine dose-effect curves (1.0 – 32.0 mg/kg) on 
56
o
 C hotplate. Abscissa: dose of morphine in milligrams per kilogram. Ordinate: percent 
maximum possible effect 
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Fig. 2.2 Effect of the CB1 antagonist SR141716A on morphine antinociception in the 
hotplate assay. Abscissa: treatment. Ordinate: mean response latency in seconds. Asterisk 
denotes statistical significance compared with saline. Double asterisk denotes statistical 
significance compared with morphine alone 
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Fig. 2.3 Acetic acid-induced writhing in CB1 KO and WT mice. Top, writhing in 
response to intraperitoneal injection of 0.56% acetic acid. Ordinate: mean number of 
writhes. Asterisk denotes statistical significance compared with WT (p<0.05). Bottom, 
effects of morphine on writhing expressed as percent inhibition of writhing. Abscissa: 
dose of morphine in milligrams per kilogram. Ordinate: percent inhibition of writhing. 
Bottom inset, effects of morphine on writhing (raw data) 
 
  
36 
 
Fig. 2.4 Effect of the CB1 antagonist SR141716A on morphine antinociception in the 
writhing assay. Abscissa: treatment. Ordinate: mean number of writhes. Asterisk denotes 
statistical significance compared with saline. Double asterisk denotes statistical 
significance compared with morphine alone 
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Fig. 2.5 Acetic acid-suppressed feeding in CB1 KO and WT mice. Top, non-suppressed 
feeding after saline and 1.0 mg/kg morphine. Ordinate: mean grams consumed per gram 
of body weight. Asterisk denotes statistical significance compared with WT (p<0.05). 
Bottom, effects of morphine on acetic acid-suppressed feeding expressed as percent 
control. Abscissa: dose of morphine in milligrams per kilogram. Ordinate: percent control 
consumption. Bottom inset, effects of morphine on acetic acid-suppressed feeding (raw 
data) 
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Fig. 2.6 Effect of the CB1 antagonist SR141716A on morphine antinociception in the 
feeding assay. Top, non-suppressed feeding after saline and 3.0 mg/kg SR141716A. 
Abscissa: treatment. Ordinate: mean grams consumed per gram of body weight. Asterisk 
denotes statistical significance compared with saline. Bottom, morphine alone and in 
combination with SR141716A. Abscissa: treatment. Ordinate: mean grams consumed per 
gram of body weight 
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Fig. 2.7 Acetic acid-suppressed wheel-running in CB1 KO and WT mice. Top, non-
suppressed wheel-running after saline and 3.2 mg/kg morphine. Ordinate: mean wheel 
revolutions. Asterisk denotes statistical significance compared with WT (p<0.05). 
Bottom, effects of morphine on acetic acid-suppressed wheel-running expressed as 
percent control. Abscissa: dose of morphine in milligrams per kilogram. Ordinate: 
percent control running. Bottom inset, effects of morphine on acetic acid-suppressed 
wheel-running (raw data) 
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Fig. 2.8 Effect of the CB1 antagonist SR141716A on morphine antinociception in the 
wheel-running assay. Top, non-suppressed running after saline, 1.0 mg/kg morphine and 
3.0 mg/kg SR141716A. Abscissa: treatment. Ordinate: mean wheel revolutions. Bottom, 
morphine alone and in combination with SR141716A. Abscissa: treatment. Ordinate: 
mean wheel revolutions. Asterisk denotes statistical significance compared with saline. 
Double asterisk denotes statistical significance compared with morphine alone 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER 3 
 
EXPERIMENT 2: Behavioral effects of anandamide modulation and interactions 
with morphine: pain-elicited behaviors 
ABSTRACT 
Rationale The endogenous cannabinoid system has received attention from researchers 
interested in basic pain mechanisms as well as those interested in developing new 
therapeutics. Drugs that inhibit endocannabinoid degradation produce antinociception in 
a variety of models, and for the most part, do so without producing other effects 
associated with CB1 agonists. Recent findings suggesting that endogenous cannabinoids 
modulate the antinociceptive effects of morphine have further increased interest in this 
system. 
Objectives The FAAH inhibitor, URB597 and the AEA uptake, inhibitor AM404, were 
examined in two assays of pain-elicited behavior: the hotplate assay and the acetic acid-
induced writhing assay. In order to determine if anandamide modifiers produce effects 
comparable to a direct CB1 agonist, the effects of the CB1 agonist, CP55940 were also 
examined. In addition, based on evidence that endogenous cannabinoids might modulate 
the antinociceptive effects of morphine, we tested the hypothesis that blockade of AEA 
degradation and uptake would enhance morphine’s antinociceptive effects. 
Results The FAAH inhibitor, URB597 and  the AEA uptake inhibitor, AM404, were 
effective to varying degrees in the writhing assay, but neither had effects in the hotplate 
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assay. The CB1 agonist CP55940 was effective in both assays, and also enhanced the 
effects of morphine in both assays. URB597 enhanced the antinociceptive effects of 
morphine in the acetic acid-induced writhing assay, but did not alter morphine’s effects in 
the hotplate assay. AM404 did not alter morphine’s effects in either assay. 
Conclusions The present findings are in agreement with the well-established efficacy of 
CB1 agonists in assays of pain-elicited behavior, as well as findings indicating that CB1 
agonists enhance the effects of morphine in these assays. In addition, this study 
demonstrates that inhibition of FAAH enhances the effects of morphine in a preclinical 
pain assay that uses a chemical noxious stimulus, which is consistent with recent findings 
that suggest a role for endogenous cannabinoids in the antinociceptive effects of 
morphine. 
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INTRODUCTION 
 Agonists at type 1 cannabinoid (CB1) and opioid receptors produce similar 
behavioral effects that include antinociception (Cox and Welch, 2004; Fischer et al., 
2008a), disruption of normal locomotor activity (Pascual et al., 2005; Smith et al., 2009), 
effects on food consumption (Järbe and DiPatrizio, 2005; Li et al., 2006), and 
interference with thermoregulation (Wang et al., 2008; Diaz et al., 2009). Moreover, 
agonists of both types of receptors serve as reinforcers in self-administration paradigms 
(Negus and Rice, 2008; Justinova et al., 2008) and produce conditioned place preference 
(Braida et al., 2001; Carrigan and Dykstra, 2007). 
 It is well-established that CB1 and opioid receptor agonists interact in assays of 
antinociception. For instance, exogenous cannabinoid agonists such as delta-9-
tetrahydrocannabinol (9-THC) potentiate the effects of morphine in the mouse tail-flick 
test (Cichewicz and McCarthy, 2003), the rat paw pressure test (Cox et al., 2007), and in 
the rat formalin test (Finn et al., 2004). Such interactions are interesting due to their 
therapeutic potential in the treatment of pain (Welch, 2009), but enthusiasm is tempered 
by the fact that CB1 agonists also interact with opioids to potentiate effects on other 
endpoints. This includes the potentiation of opioid effects in assays examining alterations 
locomotor activity (Finn et al., 2004), as well as in paradigms designed to examine the 
abuse potential of drugs (Norwood et al., 2003; Manzanedo et al., 2004; Solinas et al., 
2005). 
 Recent research implicates the endogenous cannabinoid system in mediating pain 
responses. Genetic (Cravatt et al., 2001; Lichtman et al., 2004) and pharmacological 
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(Lichtman et al., 2004; Costa et al., 2006, 2010) manipulations that inhibit the activity of 
FAAH or inhibit AEA uptake result in increased levels of AEA that are accompanied by 
antinociception that is dependent on CB1 receptors. Interestingly, this effect is typically 
not accompanied by catalepsy, hypothermia and other effects that are associated with the 
administration of CB1 agonists (Kathuria et al., 2003; Jayamanne et al., 2006). 
 The results of more recent studies indicate that endogenous cannabinoids might 
modulate the antinociceptive effects of opioids. For instance, CB1 antagonists attenuate 
morphine-induced antinociception in the hotplate and writhing tests (Miller et al., under 
review), the tail-flick test (Pacheco et al., 2009) and hyperalgesia models (Pacheco et al., 
2008). In addition, exogenously administered AEA, in combination with the FAAH 
inhibitor URB597 enhances the antinociceptive effects of morphine in the tail-flick test 
(Haller et al., 2008). Moreover, methylarachidonoylflurophosphate (MAFP), which 
inhibits the degradation of the endogenous cannabinoids AEA and 2-
arachidonoylethanolamine (2-AG), enhances the antinociceptive effects of morphine in 
the tail-flick test and in hyperalgesia models (Pacheco et al., 2008, 2009).  
 Based on these findings, the present study has two goals. First, in order to 
compare the effects of a FAAH inhibitor, URB597 and an AEA uptake inhibitor, AM404, 
with a direct CB1 agonist, CP55940, dose-effect curves for each drug were determined in 
two preclinical pain models: the hotplate assay and the acetic acid-elicited writhing assay. 
In addition, the role of CB1 receptors in the effects of these drugs was examined by the 
administration of the CB1 antagonist, SR141716A. Second, based on evidence that 
endogenous cannabinoids modulate the antinociceptive effects of morphine we tested the 
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hypothesis that blockade of AEA degradation and uptake would enhance morphine’s 
antinociceptive effects in these models. 
METHODS 
Subjects 
 Male C57BL/6 mice purchased from the Jackson Laboratory and bred in house 
were group housed in the animal facilities of the Department of Psychology at the 
University of North Carolina at Chapel Hill. Mice of approximately 12 weeks of age at 
the beginning of testing were used in these experiments, and had free access to food and 
water except where specified by the experimental protocols below. Lights were 
programmed on a 12 h light/dark cycle with lights off at 7:00am. All experiments took 
place during the dark cycle. Animal protocols were approved by the institutional animal 
care and use committee, and the methods were in accord with the “Guide for the Care and 
Use of Laboratory Animals” (Institute of Laboratory Animal Resources, Commission on 
Life Sciences, National Research Council, 1996) 
Experimental Procedures 
Hotplate 
 Mice were group housed and had free access to food and water for these 
experiments. Prior to testing, mice were habituated to the testing room and handling for 
two days. On the test day antinociception was assessed using a hotplate analgesia meter 
(25.3 X 25.3 cm; Columbus Instruments, Columbus, OH). During the hotplate test the 
mouse was placed onto the surface of the apparatus and the latency to lick or flutter the 
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hind paws, or to jump from the hotplate surface was recorded. Responses were measured 
to the nearest 0.1 s and predetermined cutoff time of 20 s was defined as the maximum 
trial duration in order to prevent tissue damage. Immediately following termination of a 
trial, mice were removed from the apparatus and returned to the home cage.  
 Drug effects were determined at a hotplate temperature of 56±0.1°C. Responses 
were measured 30 and 15 m prior to drug administration, and the latencies from these 
trials were averaged to yield one baseline value. During dose-effect determination for 
morphine (0.32-32.0) and CP55940 (0.032-3.2), cumulative doses were administered 30 
m apart in half log increments. For URB597 (0.1-10.0) and AM404 (0.32-10.0) doses 
were administered acutely and time-courses were determined. In experiments examining 
the cannabinoid compounds in combination with morphine, ineffective doses of 
CP55940, URB597, and AM404 were administered 15 m prior to the commencement of 
cumulative dosing of morphine as described above. In all experiments, when CP55940, 
URB597, or AM404 produced a significant effect or produced changes the morphine 
dose-effect curve, the effects of pretreatment with the CB1 antagonist SR141716A were 
determined. In this assay, 3.0 mg/kg SR141716A was administered 75 m prior to testing. 
Our laboratory has previously demonstrated that this dose of SR141716A does not alter 
hotplate latencies under these conditions (Miller et al., under review). The effect of each 
treatment is expressed as the percentage of the maximum possible effect (%MPE): 
[postdrug latency (s) – baseline latency (s)] / [20 – baseline latency (s)]. 
Acetic acid-induced writhing 
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 Mice were group housed and had free access to food and water until 23 and 5 h 
prior to testing, respectively. Mice were habituated to the testing room and handling for 
two days prior to testing. In addition, mice were given a 30 m session of access to 32% 
liquid nutrition (Vanilla flavor, CVS brand) on the day prior to testing. Food and water 
deprivation and access to liquid nutrition occurred due to the fact that data for acetic acid-
suppressed feeding were collected in these animals, during the same session (see 
Experiment 3). 
 On the test day, separate groups of mice were injected with saline or morphine 
(0.1 – 3.2 mg/kg; 45 m prior to the session), CP 55940 (0.01-0.32; 1 h prior to the 
session), URB597 (0.32-10.0; 1 h prior to the session), and AM404 (1.0-10.0; 1 h prior to 
session). In experiments examining the cannabinoid compounds in combination with 
morphine, the pretreatment times above were maintained and ineffective doses of 
CP55940, URB597 and AM404 were administered. In experiments examining the effects 
of SR141716A, 3.0 mg/kg of the antagonist was administered 75 m prior to testing. 
Immediately prior to the session, mice were injected with 0.56% acetic acid or saline in 
control experiments. Following this injection, mice were immediately placed into clean 
polycarbonate mouse cages (11.5” X 7.5” X 5”; Allentown Inc, Allentown, NJ) 
containing dishes of 32% liquid nutrition, and their behavior was videotaped for 30 m. 
Following the session, the tapes were viewed and the number of writhes was recorded. 
Writhes were operationally defined as an elongation of the body with simultaneous 
extension of the hind limbs. The effect of each treatment is expressed as percent 
inhibition of writhing (% Inhibition): [((writhes in saline treated mice - writhes in drug 
treated mice) / writhes in saline treated mice) X 100]. 
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Drugs 
 Morphine sulphate, URB597 and SR141716A were provided by the National 
Institute on Drug Abuse (Bethesda, MD, USA). AM404 was purchased from Tocris 
(Ellisville, MO) and CP 55940 was purchased from Sigma Aldrich (St. Louis, MO). 
Acetic acid was purchased from Fischer Scientific (Pittsburgh, PA) and diluted in 0.9% 
saline for intraperitoneal administration (0.1 ml/10g). Morphine, CP55940, URB597, 
AM404, and SR141715A were injected subcutaneously at a volume of 0.1 ml/10 g. 
Data Analysis 
 Data are expressed as mean (±SEM) % MPE or % Inhibition, depending on the 
assay (see above). The dose required to produce a 50% maximal effect (ED50) was 
derived using log-linear interpolation when possible, and differences in potency were 
determined and expressed as a potency ratio with 95% confidence limits. In instances in 
which determination of ED50s was not possible, one- and two-way ANOVAs were used 
to determine drug effects. In these instances, comparisons were conducted using Fisher’s 
protected least significant difference test. All statistical analyses were conducted with an 
alpha level of significance set at p < 0.05. 
RESULTS 
 Fig. 3.1A shows the effects of morphine, CP55940, URB597 and AM404 in the 
hotplate assay. Morphine [ED50(95%CL) = 9.03(7.04-11.59)] produced dose-dependent 
increases in %MPE, as did CP55940 [ED50(95%CL) = 0.49(0.30-0.81)]. URB597 and 
AM404 did not produce antinociception in the hotplate assay (data shown are from the 1 
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h time point, consistent with the following experiments). As shown in Fig. 3.1B, The 
CB1 antagonist, SR141716A significantly attenuated the effects of CP55940 [t(14) = 
8.03, p < 0.05].  
 Fig. 3.2A shows that pretreatment with 0.1 mg/kg CP55940, which was 
ineffective when administered alone in this assay, produced a significant leftward shift in 
the morphine dose-effect curve and this effect was attenuated by SR141716A. Neither 
URB597 nor AM404 altered morphine’s antinociceptive effects in the hotplate assay (Fig 
3.2B and 3.2C; Table 3.1). 
 Fig. 3.3A shows that Morphine, CP55940, URB597 and AM404 inhibited acetic 
acid-induced writhing to varying degrees. These experiments yielded ED50(95%CL) 
values of 0.42(0.28-0.65) for morphine, 0.03(0.01-0.08) for CP55940, and 1.30(0.92-
1.84) for URB597. AM404 partially, but significantly inhibited the writhing response 
[F(3,22) = 3.37, p < 05] at doses of 3.2 and 10.0 mg/kg. Fig.3.3B, C, and D shows that 
3.0 mg/kg SR141716A significantly attenuated the effects of CP55940 [t(9) = 6.8, p < 
0.05], URB597 [t(12) = 4.5, p < 0.05], and AM404 [t(10) = 2.3, p < 0.05]. 
Fig. 3.4A and 3.4B shows that pretreatment with 0.01 mg/kg CP55940 and 0.32 
mg/kg URB597, neither of which was effective when administered alone, produced 
significant leftward shifts in the morphine dose-effect curve in the writhing assay. 
ED50(95%CL) and potency ratios for these combinations are shown in table 3.2. In 
addition, 3.0 mg/kg SR141716A attenuated the effects of 0.32 mg/kg morphine in 
combination with CP55940 [t(11) = 2.2, p < 0.05] and URB597 [t(11) = 2.2, p < 0.05]. 
AM404 did not alter morphine’s effects in this assay (Fig. 3.4C; Table 3.2). 
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DISCUSSION 
 The primary findings of this study were that the FAAH inhibitor, URB597 and the 
AEA uptake inhibitor, AM404, were effective to varying degrees at inhibiting the 
writhing response to an acetic acid injection, but did not alter response latencies in the 
hotplate assay.  On the other hand, the CB1 agonist CP55940 was effective in both 
assays. In addition, whereas CP55960 enhanced morphine’s antinociceptive effects in 
both assays, URB597 only enhanced morphine’s antinociceptive effects in the writhing 
assay, and AM404 did not alter morphine’s antinociceptive effects at all. 
 The results observed with CP55940 are consistent with well-established findings 
demonstrating the efficacy of CB1 agonists in pain assays that use a variety of noxious 
stimuli (Lichtman and Martin, 1991a, 1991b; Welch et al., 1998). On the other hand, the 
present findings suggest that antinociception resulting from administration of URB597 
and AM404 may be dependent on the assay and/or nature of the noxious stimulus used to 
examine the drugs’ effects. Recent work with a peripherally acting FAAH inhibitor, 
URB937, may provide insights regarding these differences (Clapper et al., 2010). The 
Clapper et al. study showed that inhibition of AEA breakdown can produce peripheral 
antinociception in the writhing model as well as other neuropathic and inflammatory pain 
models, but does not alter latencies in the hotplate assay. The present studies did not use 
peripherally restricted drugs, but along with the findings by Clapper et al. (2010) and 
studies demonstrating that inflammatory stimuli produce site-specific elevations in AEA 
(Mitrirattanakul et al., 2006; Agarwal et al., 2007), these findings suggest that 
pharmacological enhancement of AEA activity may be amplified in the presence of 
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inflammatory and/or tonic noxious stimuli. The amplification of an endogenous response 
to one type of noxious stimulus (i.e. acetic acid) but not another (i.e. acute thermal pain) 
by URB597 and AM404 may provide an explanation for the effects observed with these 
drugs in the present studies.  
 Previous studies have examined the interaction of the cannabinoid and opioid 
systems by administering CB1 agonists in combination with morphine and have 
consistently shown that CB1 agonists enhance the antinociceptive effects of morphine in 
assays of pain-elicited behavior (Smith and Martin, 1992; Welch and Stevens, 1992; 
Smith et al., 1994b; Welch et al., 1995; Massi et al., 2001). More recent studies showing 
that CB1 antagonists attenuate the antinociceptive effects of morphine, provide evidence 
that endogenous cannabinoids are involved in the antinociceptive effects of morphine 
(Miller et al., under review; Pacheco et al., 2008, 2009). Moreover, morphine’s 
antinociceptive effects are enhanced when the metabolism of AEA is inhibited (Pacheco 
et al., 2008, 2009; Haller et al., 2008).  
 Consistent with these findings, doses of CP55940 that were ineffective when 
administered alone, enhanced morphine’s antinociceptive effects in the hotplate and 
writhing assays, and a dose of URB597 that was ineffective when administered alone, 
enhanced morphine’s antinociceptive effects in the writhing assay. These enhancements 
appear to be CB1 receptor-mediated since they were blocked by the CB1 antagonist 
SR141716A. Interestingly, URB597 did not alter morphine’s antinociceptive effects in 
the hotplate assay, and AM404 did not alter morphine’s effects in either assay. 
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 The influence of noxious stimuli on the interaction of URB597 and morphine may 
be related to the mechanisms discussed above regarding the different effects of URB597 
and AM404 in the hotplate and writhing assays when administered alone. In the case of 
URB597, the enhancement of AEA levels may only be sufficient to alter morphine’s 
antinociceptive effects when AEA levels are already elevated as part of an endogenous 
response to specific noxious stimuli (i.e. acetic acid). Interestingly, opioid administration 
has been shown to alter AEA levels as well (Vigano et al., 2004); however, the influence 
of opioid administration, inflammatory noxious stimuli, and disruption of FAAH 
degradation, in combination, on AEA levels has not been determined. 
 The fact that AM404 did not alter morphine’s antinociceptive effects is in contrast 
to our findings with URB597 and other studies that demonstrate that enhancement of 
AEA levels can alter the antinociceptive effects of morphine (Pacheco et al., 2008, 2009; 
Haller et al., 2008). Though the exact mechanism is unknown, as an AEA uptake 
inhibitor, AM404 enhances AEA levels via a mechanism that is distinct from FAAH 
inhibitors like URB597. Nonetheless, AM404 and URB597 are capable of producing 
similar changes in AEA levels, in vivo, at the doses and time courses used here (Fegley et 
al., 2004a, 2005). AM404 also serves as a substrate for FAAH (Fegley et al., 2004a) and 
binds to, but does not activate CB1 (Khanolkar et al., 1996; Beltramo et al., 1997). 
Effects beyond those on the accumulation of AEA may contribute to the differing effects 
of AM404 and URB597 observed here. 
 These findings show that pharmacological inhibition of FAAH and to a lesser 
extent, prevention of AEA uptake, result in antinociception in the acetic acid-induced 
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writhing assay that is mediated at least in part by CB1 receptors. In addition, these 
experiments show that inhibition of FAAH enhances morphine’s antinociceptive effects 
in this model. These studies, together with other recent findings, suggest that FAAH 
inhibition may increase AEA levels to a level that produces antinociception and 
enhancement of opioid antinociception in a manner that is dependent on the nature of 
noxious stimuli that are employed. 
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Table 3.1 ED50 (95%CL) values and potency ratios resulting from combined 
administration of morphine with CP55940, URB597, and AM404 in the hotplate assay. 
Hotplate assay. Morphine in combination with CP55940, 
URB597, and AM404 
 ED50(95%CL) Potency Ratio (95%CL) 
Morphine 9.03(7.04-11.59) - 
+ 0.032 CP55940 9.83(7.90-12.23) 1.09(0.80-1.49) 
+ 0.1 CP55940 2.60(1.65-4.08) 3.56(2.14-5.92)* 
+ 1.0 URB597 6.55(4.94-8.69) 1.31(0.93-1.85) 
+ 3.2 URB597 7.67(5.87-10.02) 1.17(0.83-1.64) 
+ 10.0 URB597 8.79(6.62-11.67) 1.02(0.72-1.45) 
+ 3.2 AM404 6.61(4.77-9.16) 1.28(0.89-1.85) 
+ 5.6 AM404 5.92(4.01-8.75) 1.41(0.96-2.08) 
+ 10.0 AM404 6.25(4.76-8.22) 1.38(0.99-1.94) 
+ 17.0 AM404 8.87(7.19-10.94) 1.03(0.75-1.41) 
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Table 3.2 ED50 (95%CL) values and potency ratios resulting from combined 
administration of morphine with CP55940, URB597, and AM404 in the writhing assay. 
Writhing assay. Morphine in combination with CP55940, 
URB597, and AM404 
 ED50(95%CL) Potency Ratio (95%CL) 
Morphine 0.42(0.28-0.65) - 
+ 0.01 CP55940 0.16(0.09-0.29) 2.77(1.62-4.82)* 
+ 0.32 URB597 0.17(0.10-0.28) 2.44(1.49-4.02)* 
+ 1.0 AM404 0.38(0.19-0.76) 1.12(0.64-1.95) 
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Fig. 3.1 Effects of CP55940, URB597, AM404 and morphine in the hotplate assay. 
Ordinate: % maximum possible effect. Abscissa: A dose (mg/kg) of each drug 
administered alone. Data points above V/S represent vehicle and saline. B Dose (mg/kg) 
of CP55940 in combination with SR141716A.  
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Fig. 3.2 Effects of morphine alone and in combination with CP55940, URB597 and 
AM404 in the hotplate assay. Ordinate: % maximum possible effect. Abscissa: A Dose 
(mg/kg) of morphine administered in combination with 0.1 mg/kg CP55940 and 3.0 
mg/kg SR141716A. B Dose (mg/kg) of morphine administered in combination with 1.0, 
3.2 and 10.0 mg/kg URB597. C Dose (mg/kg) of morphine administered in combination 
with 3.2, 5.6, 10.0 and 17.0 mg/kg AM404 
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Fig. 3.3 Effects of CP55940, URB597, AM404 and morphine in the writhing assay. 
Ordinate: % inhibition of writhing. Abscissa: A dose (mg/kg) of each drug administered 
alone. B Dose (mg/kg) of CP55940 administered in combination with SR141716A. C 
Dose (mg/kg) of URB597 administered in combination with SR141716A. D Dose 
(mg/kg) of AM404 administered in combination with SR141716A 
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Fig. 3.4 Effects of morphine alone and in combination with CP55940, URB597 and 
AM404 in the writhing assay. Ordinate: % inhibition of writhing. Abscissa: A Dose 
(mg/kg) of morphine administered in combination with 0.01 mg/kg CP55940 and 3.0 
mg/kg SR141716A. B Dose (mg/kg) of morphine administered in combination with 0.32 
mg/kg URB597. C Dose (mg/kg) of morphine administered in combination with 1.0 
mg/kg AM404. Asterisk indicates that the addition of SR141716A results in a significant 
difference from morphine + CP55940 or morphine + URB597 
  
 
CHAPTER 4 
 
EXPERIMENT 3: Behavioral effects of anandamide modulation and interactions 
with morphine: pain-suppressed and schedule-controlled behavior 
ABSTRACT 
Rationale Agonists at type 1 cannabinoid receptors produce antinociception and other 
effects including disruption of locomotor activity, catalepsy, and disruption of 
thermoregulation. Drugs that inhibit the degradation of the endogenous cannabinoid 
ligand anandamide, produce antinociception but typically do not produce other effects 
associated with CB1 agonists. It has been shown that CB1 agonists and anandamide 
modifiers enhance the antinociceptive effects of morphine. There is also evidence that 
CB1 agonists alter opioid effects on behavioral endpoints unrelated to nociception, but to 
date, the limited data available suggests that anandamide modifiers selectively alter 
morphine antinociception. 
Objectives To determine if pharmacological inhibition of AEA degradation specifically 
results in antinociception, the effects of URB597 and AM404 were examined in two 
assays of pain-suppressed behavior (acetic acid-suppressed feeding and wheel-running) 
and an assay of schedule-controlled behavior. These assays were used to examine 
URB597 and AM404 in combination with morphine in order to determine if AEA 
modulates the effects of morphine on behaviors other than pain-elicited behaviors. The 
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effects of the CB1 agonist, CP55940 were determined in order to examine the specificity 
of the interactions between morphine and a direct agonist at CB1 receptors. 
Results URB597, AM404 and morphine attenuated the suppression of wheel-running that 
resulted from administration of acetic acid; however only URB597 was effective at 
blocking the suppression of feeding. CP55940 was not effective in the assays of pain-
suppressed behavior. URB597 was the only drug to enhance the effects of morphine in 
either of these assays. The CB1 agonist CP55940 and morphine dose-dependently 
decreased responding in the assay of schedule-controlled behavior, but URB597 and 
AM404 did not alter response rates. In addition, CP55940 but not URB597 or AM404 
significantly enhanced morphine’s rate-decreasing effects.  
Conclusions These data are consistent with findings suggesting that modification of AEA 
availability, particularly through FAAH inhibition, produces antinociception without 
nonspecific effects that are associated with CB1 agonists. In addition, these findings 
provide evidence that AEA specifically modulates morphine’s antinociceptive effects. On 
the other hand, these studies suggest that a direct CB1 agonist enhances morphine’s 
effects on behavioral endpoints unrelated to antinociception. 
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INTRODUCTION 
 Recent research reveals that enhancement of endogenous cannabinoid signaling 
can produce antinociception. Pharmacological manipulations (Lichtman et al., 2004; 
Costa et al., 2006, 2010) that inhibit the activity of FAAH or inhibit AEA uptake result in 
increased levels of AEA that are accompanied by type 1 cannabinoid (CB1) receptor-
dependent antinociception. To date, most evidence suggests that this effect is typically 
not accompanied by catalepsy, hypothermia, or changes in feeding or locomotor activity 
(Kathuria et al., 2003; Jayamanne et al., 2006; Clapper et al., 2010), which are other 
behavioral effects that are associated with the administration of CB1 agonists. 
 The results of several studies indicate that endogenous cannabinoids modulate the 
antinociceptive effects of opioids. Exogenously administered AEA, in combination with 
the FAAH inhibitor URB597 (Haller et al., 2008) enhances the antinociceptive effects of 
morphine. In addition, methylarachidonoylflurophosphate (MAFP), which inhibits the 
degradation of the endogenous cannabinoids AEA and 2-arachidonoylethanolamine (2-
AG), enhances the antinociceptive effects of morphine (Pacheco et al., 2008, 2009) as 
well. Our laboratory has also shown (Experiment 2) that URB597 enhances the 
antinociceptive effects of morphine in the acetic acid-induced writhing assay, though 
there was no enhancement of morphine’s antinociceptive effects in the thermal hotplate 
assay. 
 Consistent with the emerging data regarding manipulations of endogenous 
cannabinoid signaling, it is well-established that CB1 and opioid receptor agonists 
interact in assays of antinociception. For instance, exogenous cannabinoid agonists such 
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as delta-9-tetrahydrocannabinol (9-THC) potentiate the effects of morphine in the 
mouse tail-flick test (Cichewicz and McCarthy, 2003) and the rat paw pressure test (Cox 
et al., 2007). However, there is also evidence suggesting that CB1 agonists alter the 
effects of opioids on other endpoints. For instance, CB1 agonists enhance morphine 
conditioned place preference (Manzanedo et al., 2004), the reinforcing efficacy of heroin 
in a self-administration paradigm (Solinas et al., 2005), and morphine’s effects on 
locomotor activity (Ayhan et al., 1979).  
 It is well known that drug effects are determined by the behavioral endpoint being 
examined (Stevenson et al., 2003, 2005; Fischer and Dykstra, 2006; Fischer et al., 
2008b), but as mentioned above, there is evidence that direct CB1 agonists enhance 
opioid effects across a variety of behavioral endpoints. Fewer studies have examined the 
effects of modification of AEA levels on the behavioral effects of morphine, but the 
FAAH inhibitor URB597 and the AEA uptake inhibitor AM404 do not alter the 
reinforcing effects of heroin (Solinas et al., 2005). Therefore, it may be the case that 
drugs that modify AEA, may enhance morphine antinociception without enhancing some 
of morphine’s non-antinociceptive effects. 
 Recently researchers have demonstrated that preclinical pain models that examine 
pain-suppressed behavior may be useful in separating antinociceptive effects of drugs 
from non-specific effects such as disruptions of locomotor activity (Stevenson et al., 
2006, 2009). The latter effects are a potential source of confounds in traditional pain 
models that utilize pain-elicited behavior. In addition, since antinociception and effects 
on locomotor activity are consequences of the administration of CB1 agonists and 
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morphine, assays of pain-suppressed behavior might be particularly helpful in separating 
antinociception from non-specific effects. 
 Accordingly, the present study has two goals. First, in order to extend the findings 
from experiment 2, the effects of administration of a direct CB1 agonist, CP55940 and 
AEA modifiers, URB597 and AM404, were determined on a variety of behavioral 
endpoints. Dose-effect curves were determined for each drug in two assays of pain-
suppressed behavior (pain-suppressed feeding and pain-suppressed wheel-running). In 
addition, an assay of food-maintained schedule-controlled behavior was used to 
determine the effects of these drugs on a behavioral endpoint unrelated to nociception. 
The role of CB1 receptors in the effects of these drugs was assessed by the administration 
of the CB1 antagonist, SR141716A. Second, based on the evidence that AEA modifiers 
enhance the antinociceptive effects of morphine, but not effects unrelated to 
antinociception, we tested the hypothesis that blockade of AEA degradation and uptake 
would enhance morphine’s antinociceptive effects in the assays of pain-suppressed 
behavior, but would not alter morphine’s rate-decreasing effects in the assay of schedule-
controlled behavior. 
METHODS 
Subjects 
 Male C57BL/6 mice purchased from the Jackson Laboratory and bred in house 
were group housed in the animal facilities of the Department of Psychology at the 
University of North Carolina at Chapel Hill. Mice of approximately 12 weeks of age at 
the beginning of testing were used in these studies. Mice had free access to food and 
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water except for the 2.5 h prior to experimental sessions. Lights were programmed on a 
12 h light/dark cycle with lights off at 7:00am. All experiments took place during the 
dark cycle. Animal protocols were approved by the institutional animal care and use 
committee, and the methods were in accord with the “Guide for the Care and Use of 
Laboratory Animals” (Institute of Laboratory Animal Resources, Commission on Life 
Sciences, National Research Council, 1996) 
Experimental Procedures 
Acetic acid-suppressed feeding 
 Mice were group housed and had free access to food and water until 23 and 5 h 
prior to testing, respectively. Mice were habituated to the testing room and handling for 
two days prior to testing. In addition, 24 h prior to testing, mice were given a 30 m 
session of free access to approximately 14 ml of 32% liquid nutrition (Vanilla flavor, 
CVS brand; composition as used: protein = 0.36 g/oz, carbohydrate = 1.6 g/oz, and fat = 
0.24 g/oz). During this session, individual mice were placed into bedding-free 
polycarbonate mouse cages that contained a glass dish containing liquid nutrition and 
were allowed to explore the testing environment and consume the liquid nutrition.  
 On the test day, separate groups of mice were injected with saline or morphine 
(0.1 – 3.2 mg/kg; 45 m prior to the session), CP 55940 (0.01-0.32; 1 h prior to the 
session), URB597 (0.32-10.0; 1 h prior to the session), and AM404 (1.0-10.0; 1 h prior to 
session). In experiments examining the cannabinoid compounds in combination with 
morphine, the pretreatment times above were maintained and ineffective doses of 
CP55940, URB597 and AM404 were administered prior to morphine. In experiments 
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examining the effects of SR141716A, 3.0 mg/kg was administered 75 m prior to testing. 
Immediately prior to the session, mice were injected with 0.56% acetic acid or saline in 
control experiments. Following the second injection mice were immediately placed into 
clean polycarbonate mouse cages (11.5” X 7.5” X 5”; Allentown Inc, Allentown, NJ) 
containing liquid nutrition for 30 m. Consumption was quantified by subtracting the 
weight of the liquid-containing dishes after the session from the weight obtained prior to 
the session. Because body size might influence consumption independent of other 
variables, this value was divided by the animals’ weight (grams of liquid consumed per 
gram of body weight). In the event of spillage, the data were discarded. The effect of 
each treatment on pain-suppressed consumption is expressed as percent of non-
suppressed consumption (% Control): [(acetic acid-suppressed consumption (g/g) / non-
suppressed consumption (g/g)) X 100]. 
Acetic acid-suppressed wheel-running 
 Mice were grouped housed in standard polycarbonate mouse cages (11.5” X 7.5” 
X 5”; Allentown Inc, Allentown, NJ) until the start of the experiments. At this time mice 
were individually housed in polycarbonate cages (14” X 10.5” X 5.5”; Tecniplast USA 
Inc., Exton, PA) containing running wheels (ENV-044, Med Associates, St. Albans, VT). 
Testing occurred after two weeks of habituation to handling and acquisition of wheel-
running behavior. On the day prior to testing (control session) mice were injected with 
saline followed 45 m later by a second injection of saline and wheel-running 
(revolutions) were recorded for 30 m. The next day (test session), 24 h after the control 
session, separate groups of mice were injected with morphine (0.32 – 3.2 mg/kg; 45 m 
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prior to the session), CP55940 (0.01-0.1; 1 h prior to the session), URB597 (0.32-10.0; 1 
h prior to the session), AM404 (1.0-10.0; 1 h prior to session) or saline/vehicle. 
Immediately prior to the session, mice were injected with 0.56% acetic acid or saline, and 
wheel-running was recorded for 30 m. In experiments examining the cannabinoid 
compounds in combination with morphine, the pretreatment times above were maintained 
and ineffective doses of CP55940, URB597 and AM404 were administered prior to 
morphine. In experiments examining the effects of SR141716A, 3.0 mg/kg was 
administered 75 m prior to testing. Acetic acid suppressed wheel-running was examined 
up to four times in each mouse with at least one week between exposures to acetic acid. 
This schedule of exposure did not have effects on wheel-running beyond the test day and 
does not produce long term disruptions of other behaviors, such as feeding (Stevenson et 
al., 2006). The effect of each treatment on pain-suppressed wheel-running is expressed as 
percent of non-suppressed wheel-running (% Control): [(acetic acid-suppressed running / 
non-suppressed running) X 100]. 
Schedule-controlled behavior 
 Mice were group housed in polycarbonate mouse cages (11.5” X 7.5” X 5”; 
Allentown Inc, Allentown, NJ) and had free access to food and water except for the 2.5 
hr preceding experimental sessions. Mice were habituated to the testing room and 
handling for two days prior to testing. Response rates in the assay of schedule controlled 
behavior were determined in mouse operant chambers (8.5" X 7.0"  X 5.0"; ENV-307W-
CT; Med Associates, St. Albens, VT) that were equipped with a grid floor, houselight, 
ventilator fan, and two nose-poke holes (capable of being illuminated from within) 
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located on either side of a liquid dipper. Stimulus lights located above each nose-poke 
hole were not used during these experiments.  
 During experimental sessions mice were placed into the test chambers for 10 m 
without any of the stimuli activated. Following this acclimation period, the ventilator fan 
was activated and the left nose-poke hole was illuminated. At this point, left nose-poke 
responses counted toward completion of a fixed ratio (FR) response requirement and 
nose-pokes on the right had no scheduled consequences. During an initial training period, 
the FR value was increased from 1 to 2 and then the terminal ratio of 4, which was used 
for the remainder of the experiments. Completion of the FR resulted in access to a liquid 
reinforcer (32% Liquid Nutrition, CVS) via the liquid dipper, and activation of the 
houselight for 8 s. In addition, the light within the left nose-poke hole was turned off 
during the 8 s reinforcer delivery period. Once the reinforcer delivery period elapsed, the 
dipper was lowered, the houselight was turned off, and the left nose-poke hole was 
illuminated signaling the next response period. Testing occurred 5 days per week and 
sessions ended after 30 m elapsed or when 100 reinforcers were earned. 
 Once response rates were stable under the FR 4 ratio of reinforcement, the effects 
of pharmacological manipulations were determined. Separate groups of mice were used 
to determine the effects of morphine (0.32 – 3.2 mg/kg), CP 55940 (0.01-0.1 mg/kg), and 
URB597 (0.32-17.0 mg/kg). Following the determination of the effects of these 
compounds, the mice were given a period of 2 weeks without receiving drugs before 
being redistributed into separate groups to determine the effects of AM404 (1.0-17.0 
mg/kg) and drug combinations. Drug effects were assessed twice a week on Tuesdays 
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and Fridays.  Drug data are expressed as a percentage of control response rates (% 
Control): [(responses per minute on test day / responses per minute on control day) X 
100]. 
Drugs 
 Morphine sulphate, URB597 and SR 141716A were provided by the National 
Institute on Drug Abuse (Bethesda, MD, USA).  AM404 was purchased from Tocris 
(Ellisville, MO), and CP 55940 was purchased from Sigma Aldrich (St. Louis, MO). 
Morphine (45 m pretreatment), CP55940 (1 h pretreatment), URB597 (1 h pretreatment), 
AM404 (1 h pretreatment), and SR141715A (75 m pretreatment) were injected 
subcutaneously at a volume of 0.1 ml/10 g. 
Data Analysis 
 Data are presented as mean (SEM) % control feeding, wheel-running, or 
responding (see above). One- and two-way ANOVAs were used to determine drug 
effects and post hoc comparisons were conducted using Fisher’s protected least 
significant difference. All statistical analyses were conducted with an alpha level of 
significance set at p < 0.05. 
RESULTS 
Table 4.1 shows that intraperitoneal injection of 0.56% acetic acid resulted in a 
significant decrease in feeding behavior [t(10) = 11.32, p < 0.05] with mean consumption 
(±SEM) of 0.01 (0.003) g of fluid per gram of body weight for mice receiving an acetic 
acid injection versus 0.11 (0.01) g/g body weight in control animals. As shown in Fig. 
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4.1A, URB597 was the only drug that attenuated the suppression of feeding produced by 
injection of acetic acid [F(4,35) = 2.24, p < 0.05] and this effect was blocked by 
SR141716A (Fig. 4.1B).  
 Fig. 4.2 shows the effects of morphine in combination with ineffective doses of 
CP55940, URB597 and AM404. CP55940 (Fig. 4.2A) and AM404 (Fig. 4.2C) did not 
alter morphine’s effects on pain-suppressed feeding. Fig. 4.2B shows, that though 
morphine had no effect on pain-suppressed feeding when administered alone, morphine 
in combination with an ineffective dose of URB597 (0.32 mg/kg) significantly attenuated 
the suppression of feeding [F(3,22) = 49.15, p < 0.05]. This effect was blocked by 3.0 
mg/kg SR141716A.  
 Table 4.1 shows the effects of various drugs and drug combinations on non-
suppressed feeding. When compared to control animals, 3.0 mg/kg SR141716A did not 
alter non-suppressed feeding under these experimental conditions. Likewise, 3.2 mg/kg 
URB597 and 0.32 mg/kg URB597 in combination with 0.32 mg/kg morphine, which 
were treatments that were effective at attenuating the suppression of feeding by acetic 
acid , did not alter non-suppressed feeding. 
 Table 4.2 shows that intraperitoneal injection of acetic acid also significantly 
suppressed wheel-running behavior [t(14) = 4.04, p < 0.05]. Mean (±SEM) wheel 
revolutions was 1101.75 (210.30) for control animals whereas wheel-running was 
completely suppressed in mice exposed to 0.56% acetic acid. Fig. 4.3A shows that 
URB597 [F(4,35) = 4.03, p < 0.05], morphine [F(4,34) = 4.82, p < 0.05] and AM404 
[F(3,28) = 6.82, p < 0.05], but not CP55940 significantly attenuated the suppression of 
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wheel-running that resulted from i.p. injection of acetic acid. Fig. 4.3B and 4.3C shows 
that SR141716A significantly antagonized the effects of URB597 [t(11) = 2.60, p < 0.05] 
and AM404 [t(14) = 2.55, p < 0.05]. Doses of each drug that significantly attenuated the 
suppression of wheel-running by injection acetic acid were examined in mice in the 
absence of acetic acid, and each of these drugs had no effect on non-suppressed wheel-
running (table 4.2). 
CP55940 (Fig. 4.4A) and AM404 (Fig. 4.4C) did not alter morphine’s effects in 
the wheel-running assay. Fig. 4.4B shows that 0.32 mg/kg URB597, which had no effect 
when administered alone, significantly altered the morphine dose effect curve in the 
wheel-running assay [F(1,46) = 6.53, p < 0.05]. Specifically, 0.56 mg/kg morphine in 
combination with 0.32 mg/kg URB produced a greater effect on wheel running than did 
this dose of morphine alone. SR1411716A antagonized this effect.  
 Fig. 4.5A shows the effects of morphine, CP55940, URB597, and AM404 in the 
assay of schedule-controlled behavior. ED50(95%CL) values were 4.36 (3.47-5.48) for 
morphine and 0.05 (0.05-0.06) for CP55940. URB597 and AM404 had no effect on 
responding. The rate-decreasing effect of CP55940 was antagonized by SR141716A (Fig. 
4.5B). 
 Fig. 4.6A shows that an ineffective dose of CP55940 (0.032 mg/kg) significantly 
shifted the morphine dose-effect curve [ED50(95%CL) = 1.05 (0.81-1.45)] to the left 
yielding a potency ratio (95%CL) of 4.16 (3.01-5.75). Pretreatment with 3.0 mg/kg 
SR141616A, which had no effect on response rates when administered alone, attenuated 
the rate-decreasing effects of a combination of 0.032 mg/kg CP55940 and 3.2 mg/kg 
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morphine. URB597 (Fig. 4.6B) and AM404 (Fig. 4.6C) did not alter morphine’s rate-
decreasing effects. 
DISCUSSION 
 The primary findings of this study were that the FAAH inhibitor, URB597 and the 
AEA uptake inhibitor, AM404, were effective to varying degrees in the assays of pain-
suppressed behavior, but neither drug disrupted food-maintained schedule-controlled 
behavior. On the other hand, CP55940 was not effective in the assays of pain-suppressed 
behavior, and dose-dependently decreased response rates in the assay of schedule-
controlled behavior. In addition, URB597 and AM404 did not enhance morphine’s rate-
decreasing effects in the assay of schedule controlled behavior, but URB597 significantly 
enhanced morphine’s antinociceptive effects in the assays of pain-suppressed behavior. 
CP55940 enhanced morphine’s rate-decreasing effects, but not morphine’s 
antinociceptive effects. 
 Recent research has examined the consequences of pharmacological elevation of 
endogenous cannabinoid signaling on pain behaviors. Pharmacological manipulations 
that inhibit AEA degradation (Lichtman et al., 2004; Kinsey et al., 2009; Costa et al., 
2010) or limit AEA uptake (Costa et al., 2006) are effective in preclinical pain models. 
Interestingly, the blockade of endocannabinoid degradation does not produce many of the 
non-antinociceptive effects that are associated with CB1 agonists, such as catalepsy and 
disruption of locomotor activity (Cravatt et al., 2001; Moore et al., 2005; Russo et al., 
2007). This indicates that the behavioral endpoint used to determine the effects of these 
drugs is a determinant of their effects. 
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 The results of the present experiments are consistent with these findings. First, the 
findings obtained from the assays of pain-suppressed behavior suggest that 
pharmacological inhibition of the breakdown of AEA, particularly FAAH inhibition by 
URB597 and to a lesser extent, inhibition of AEA uptake by AM404, produces 
antinociception that is not accompanied by effects that disrupt feeding or wheel-running 
behavior. In addition, doses of these drugs that reversed acetic-acid induced suppression 
of feeding and wheel-running did not alter these behaviors when administered in the 
absence of acetic acid. This suggests that the antinociception observed here (defined for 
these models as a return toward baseline rates of behavior) is not due to non-specific 
increases in the behaviors measured by these models. In contrast, a range of doses of 
URB597 and AM404, including doses that are effective in numerous pain models and 
produces changes in AEA levels (Fegley et al., 2004a, 2005), failed to alter response rates 
in the assay of schedule-controlled behavior. Taken together, these data suggest a 
behavioral selectivity of these drugs that CB1 agonists do not possess. 
 Previous studies have examined the interaction of the cannabinoid and opioid 
systems by administering CB1 agonists in combination with morphine, and have 
consistently shown that CB1 agonists enhance the antinociceptive effects of morphine 
(Smith and Martin, 1992; Welch and Stevens, 1992; Smith et al., 1994b; Welch et al., 
1995; Massi et al., 2001). More recent studies utilizing CB1 antagonists provide evidence 
that endogenous cannabinoids are involved in the antinociceptive effects of morphine 
(Miller et al., under review; Pacheco et al., 2008, 2009). Moreover, morphine’s 
antinociceptive effects are enhanced when the metabolism of AEA is inhibited (Pacheco 
et al., 2008, 2009; Haller et al., 2008).  
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 The present studies demonstrate that URB597 enhanced morphine antinociception 
in the pain-suppressed feeding assay and in the pain-suppressed wheel-running assay in a 
CB1 receptor-mediated manner. However, URB597 did not alter morphine’s effects on 
schedule-controlled behavior. These findings suggest that enhanced activity at CB1 
receptors that results from inhibition of AEA degradation specifically enhances 
morphine’s antinociceptive effects. On the other hand, the CB1 agonist CP55940 
enhanced morphine’s rate-decreasing effects in the assay of schedule-controlled behavior. 
Together with the findings in Experiment 2, these data suggest that behavioral endpoint is 
a determinant of the interaction between morphine and drugs that modify endogenous 
cannabinoid levels, whereas CB1 agonist enhance the effects of morphine across a 
variety of endpoints. 
 The mechanisms of this selectivity warrants further research, but there is evidence 
that tonic exposure to noxious stimuli results in elevations of AEA levels in regions 
associated with pain processing (Mitrirattanakul et al., 2006; Agarwal et al., 2007). 
Therefore, it may be the case that the effects of drugs that alter AEA levels are amplified 
in areas that have implications on pain signals. Consistent with this hypothesis, there is 
recent evidence that a peripherally acting FAAH inhibitor, URB937, produces CB1-
dependent antinociception in a variety of pain models that involve tonic exposure to 
noxious stimuli, including acetic acid (Clapper et al., 2010). In addition, this peripheral 
FAAH inhibition produces CB1-dependent suppression of dorsal horn responses to 
formalin injection to the hind paw of rats (Clapper et al., 2010). Thus FAAH inhibition 
may magnify an endogenous response to noxious stimuli that includes increased AEA, 
and the resulting attenuation of pain related signaling might occur prior to the 
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involvement of the CNS. The effects of the drugs used in the present studies are not 
limited to the periphery, but the effects obtained in these studies are consistent with the 
possibility of a selective enhancement of AEA levels in areas involved in nociceptive 
processing as opposed to the wide-ranging activation of CB1 receptors resulting from 
CB1 agonists. This might explain the behavioral selectivity of the effects of AM404 and 
URB597, as well as the interactions of URB597 and morphine, that were observed here. 
 The present findings provide further evidence of the involvement of endogenous 
cannabinoids in the antinociceptive effects of morphine (Pacheco et al., 2008, 2009; 
Haller et al., 2008). It also appears that AEA involvement in the effects of morphine 
might be limited to antinociception, but thus far data regarding this hypothesis are 
limited. Further studies using different noxious stimuli, measures of antinociception, and 
behavioral endpoints are needed to fully characterize the role of endogenous 
cannabinoids in the behavioral effects of opioids. 
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Table 4.1 Liquid nutrition consumption by control mice, mice receiving 0.56% acetic 
acid in the absence of drug treatments, and mice receiving drug treatments in the absence 
of acetic acid. Asterisk indicates a significant difference from control animals   
 
Acetic Acid 
Concentration Drug Condition 
Mean (SE) 
Consumption (g/g) 
0 Saline 0.11 (0.01) 
0.56% Saline 0.01 (0.003)* 
0 3.0 mg/kg SR1417116A 0.10 (0.01) 
0 3.2 mg/kg URB597 0.09 (0.01) 
0 
0.32 mg/kg URB597 + 
0.32 mg/kg morphine 
0.09 (0.02) 
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Table 4.2 Wheel running by control mice, mice receiving 0.56% acetic acid in the 
absence of drug treatments, and mice receiving drug treatments in the absence of acetic 
acid. Asterisk indicates a significant difference from control animals 
Acetic Acid 
Concentration Drug Condition 
Mean (SE) 
Revolutions 
0 Saline 1101.75 (210.30) 
0.56% Saline 0.00 (0.00)* 
0 3.0 mg/kg SR1417116A 775.38 (178.04) 
0 1.0 mg/kg morphine 998.63 (210.30) 
0 10.0 mg/kg URB597 945.17 (242.83) 
0 10. mg/kg AM404 961.00 (266.01) 
0 
0.32 mg/kg URB597 + 
0.56 mg/kg morphine 
794.17 (104.56) 
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Fig. 4.1 Effects of CP55940, URB597, AM404 and morphine in the pain-suppressed 
feeding assay. Ordinate: % control feeding. Abscissa: A dose (mg/kg) of each drug 
administered alone. B Dose (mg/kg) of URB597 administered in combination with 
SR141716A  
 
 
 
  
79 
 
Fig. 4.2 Effects of morphine alone and in combination with CP55940, URB597 and 
AM404 in the pain-suppressed feeding assay. Ordinate: % control consumption. 
Abscissa: A Dose (mg/kg) of morphine administered in combination with 0.01 and 0.032 
mg/kg CP55940. B Dose (mg/kg) of morphine administered in combination with 0.32 
mg/kg URB597 and 3.0 mg/kg SR141716A. C Dose (mg/kg) of morphine administered 
in combination with 1.0 and 3.2 mg/kg AM404. Asterisks indicate significant difference 
relative to vehicle treated mice 
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Fig. 4.3 Effects of CP55940, URB597, AM404 alone and in combination with morphine 
in the pain-suppressed wheel-running assay. Ordinate: % control running. Abscissa: A 
dose (mg/kg) of each drug administered alone. B Dose (mg/kg) of morphine administered 
in combination with 0.01 and 0.032 mg/kg CP55940. C Dose (mg/kg) of morphine 
administered in combination with 0.32 mg/kg URB597 and 3.0 mg/kg SR141716A. D 
Dose (mg/kg) of morphine administered in combination with 1.0 mg/kg AM404 
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Fig. 4.4 Effects morphine alone and in combination with CP55940, URB597 and AM404 
in the pain-suppressed wheel running assay. Ordinate: % control running. Abscissa: 
treatment. A Dose (mg/kg) of morphine in combination with 0.01 and 0.032 mg/kg 
CP55940. B Dose (mg/kg) of morphine in combination with 0.32 mg/kg URB597 and 3.0 
mg/kg SR141716A. C Dose (mg/kg) of morphine in combination with 1.0 mg/kg 
AM404. 
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Fig. 4.5 Effects of CP55940, URB597, AM404 and morphine in the assay of schedule-
controlled behavior. Ordinate: % control responding. Abscissa: A dose (mg/kg) of each 
drug administered alone. B Dose (mg/kg) of CP55940 administered in combination with 
SR141716A.  
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Fig. 4.6 Effects of morphine alone and in combination with CP55940, URB597 and 
AM404 in the assay of schedule-controlled behavior. Ordinate: % control feeding. 
Abscissa: A Dose (mg/kg) of morphine in combination with 0.032 CP55940 and 3.0 
mg/kg SR141716A. B Dose (mg/kg) of morphine in combination with 10.0 and 17.0 
mg/kg URB597. C Dose (mg/kg) of morphine in combination with 10.0 and 17.0 mg/kg 
AM404 
 
  
 
 
CHAPTER 5 
GENERAL DISCUSSION 
 
Experimental Results 
 
 The experiments included in this project were designed with two goals in mind. 
The primary goal was to examine the role of endogenous cannabinoid signaling in the 
antinociceptive and other behavioral effects of morphine. A secondary goal was to assess 
the utility of models of pain-suppressed behavior, a relatively novel way of studying 
nociception and antinociception. 
 The first experiment used the strategy of disrupting cannabinoid signaling in order 
to determine the role of endogenous cannabinoids in morphine’s antinociceptive effects. 
Previous studies had utilized CB1 knockout mice and selective CB1 antagonists to study 
the antinociceptive effects of morphine and obtained conflicting results. Studies using 
CB1 antagonists implicated the CB1 receptor in morphine’s antinociceptive effects, 
whereas studies using knockout mice revealed no differences between wildtype mice and 
mice lacking the CB1 receptor. Procedural differences made interpretation of these 
findings difficult, particularly since the use of CB1 knockout mice to study morphine 
antinociception was limited to thermal pain assays. Experiment 1 examined the effects of 
morphine in CB1 knockout and wildtype mice in preclinical pain models that used both 
thermal and chemical noxious stimuli and measured a variety of behavioral responses to 
these stimuli. In addition, to determine whether CB1 knockout mice undergo 
developmental alterations that mask the role of this receptor in morphine’s 
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antinociceptive effects, experiments were carried out with the selective CB1 antagonist, 
SR141716A. 
 The results from experiment 1 indicate that acute disruption of CB1 activity via 
pharmacological means does alter morphine’s antinociceptive effects. In each instance in 
which morphine was efficacious, SR141716A attenuated its effect. In contrast with the 
pharmacological manipulation of CB1 receptors, but consistent with findings reported in 
the literature, knockout of the CB1 receptor had no consequences on morphine’s 
antinociceptive effects. Together with the existing research, these data suggest that 
endogenous cannabinoids acting at CB1 receptors do have a role in the antinociceptive 
effects of morphine. On the other hand, we do not have a definitive explanation for the 
results obtained in knockout mice, but it is possible that these animals develop in a 
manner that circumvents the relationship between the cannabinoid and opioid systems, at 
least with regard to pain. 
 Experiment 2 used a different strategy to examine the role of endogenous 
cannabinoids in the antinociceptive effects of morphine. Recently, drugs that limit the 
degradation of anandamide and other endogenous cannabinoids have been synthesized 
and are being used to examine the effects of enhancing anandamide activity by 
preventing its enzymatic breakdown. We used the FAAH inhibitor, URB597 and the 
AEA uptake inhibitor, AM404, to determine whether pharmacological enhancement of 
AEA activity produces a similar profile of antinociceptive effects as the CB1 agonist 
CP55940. In addition, we sought to examine the role of AEA in the antinociceptive 
effects of morphine by determining the effects of URB597 and AM404 in combination 
with morphine.  
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 Experiment 2 revealed that the antinociceptive effects of the FAAH inhibitor, 
URB597 and AEA uptake inhibitor, AM404, were dependent on the assay in which they 
were studied. Neither URB597 nor AM404 was effective in the hotplate assay, but both 
were effective to varying degrees in the writhing assay. Previous findings are mixed with 
regard to the efficacy of drugs that increase AEA levels in thermal pain assays, but the 
majority of findings suggest that these drugs produce antinociception in pain models 
involving inflammatory noxious stimuli (de Lago et al., 2002; La Rana et al., 2006).  
 In addition, experiment 2 provides support for the hypothesis that AEA modulates 
the antinociceptive effects of morphine; however this role may be dependent on the assay 
as well as the manner in which AEA levels are manipulated. URB597 enhanced the 
antinociceptive effects of morphine in the writhing assay, but neither URB597 nor 
AM404 altered morphine’s effects in the hotplate assay. The CB1 agonist, CP55940 
enhanced morphine’s antinociceptive effects in both of these assays. 
 In experiment 3, two assays of pain-suppressed behavior and an assay of 
schedule-controlled behavior were used to extend the findings from experiment 2 with 
regard to antinociception, and to provide a behavioral endpoint unrelated to 
antinociception for examining these drugs. Consistent with our hypotheses and what is 
known about these drugs, URB597 and AM404 were effective in the assays of pain-
suppressed behavior to varying degrees and did not alter response rates in the assay of 
schedule-controlled behavior. On the other hand, the CB1 agonist, CP55940 dose-
dependently decreased response rates and had no effect on pain-suppressed behavior. 
 As expected, CP55940 resulted in a significant leftward shift of the morphine 
dose-effect curve in the assay of schedule-controlled behavior, but not the assays of pain-
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suppressed behavior. AM404 did not alter the effects of morphine in any of the models 
used in this project. On the other hand, URB597 produced upward shifts in the morphine 
dose-effect curve in the pain-suppressed feeding and pain-suppressed wheel-running 
assays (indicative of enhancement), and did not alter the rate-decreasing effects of 
morphine in the assay of schedule-controlled behavior.  
 Taken together, experiments 2 and 3 suggest that unlike CP55940, URB597 
selectively enhances morphine antinociception (in models employing chemical noxious 
stimuli) without enhancing nonspecific effects such as disruption of locomotor activity. 
These findings are consistent with data suggesting a specific role of AEA in the 
antinociceptive effects of morphine. 
 
Disparities in the effects of URB597 and AM404 
 There is mounting evidence that the endogenous cannabinoid system, specifically 
the inhibition of the metabolism of endogenous cannabinoids, is a potential target for the 
treatment of pain. Among the strategies receiving attention is the pharmacological 
inhibition of FAAH. Administration of drugs that block the activity of this enzyme results 
in rapid and prolonged increases in anandamide levels (Lichtman et al., 2004; Fegley et 
al., 2005) and produces antinociception in a variety of preclinical models including the 
hotplate, tail-immersion and formalin tests (Lichtman et al., 2004) as well as neuropathic 
pain models (Kinsey et al., 2009). 
 While FAAH inhibitors disrupt the functioning of the enzyme that is primarily 
responsible for anandamide degradation, prevention of anandamide uptake is another 
strategy that may be employed to study this system. There is some controversy about the 
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mechanism of AEA uptake (i.e. active transport or a passive process), but drugs that have 
been termed anandamide uptake inhibitors, such as AM404, result in increased 
anandamide levels (Giuffrida et al., 2000), and antinociception has been demonstrated 
with AEA uptake inhibitors in the formalin test (Gühring et al., 2002; La Rana et al., 
2006), the chronic constriction injury and complete freund’s adjuvant tests (La Rana et 
al., 2006). On the other hand, the data are mixed with regard to thermal tests (Beltramo et 
al., 1997, 2000; de Lago et al., 2002; Ruggieri et al., 2008). 
 Existing behavioral and physiological data suggest that URB597 and AM404 
would have similar effects in the assays used here; however, that was not always the case. 
When both drugs were active in an assay and their effects could be compared directly, 
URB597 was typically more potent and efficacious than AM404. It is not entirely 
surprising that two drugs that alter anandamide levels via different means would produce 
different results. However, given the similar magnitude and time course of effects of 
these drugs on anandamide levels (Fegley et al., 2004a, 2005), and our hypothesis that it 
is anandamide activity at CB1 receptors that is mediating the behavioral effects of these 
drugs, this finding was not predicted. 
 The fact that AM404 is very similar in structure to anandamide (Beltramo et al., 
1997) might play a role in these differences. AM404 is also similar to anandamide in that 
both bind to CB1 receptors, though AM404 binds with lower affinity (Khanolkar et al., 
1996), and this binding is not accompanied by activation of CB1 receptors (Beltramo et 
al., 1997). In contrast, URB597 does not bind to CB1 receptors (Piomelli et al., 2006). 
Since AM404 enhances anandamide levels while binding to, but not activating CB1 
receptor, this leaves the possibility that AM404 is inhibiting the uptake of anandamide 
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while simultaneously functioning as a low affinity competitive antagonist at CB1 
receptors. To our knowledge, there are no studies that directly examine this possibility 
and this remains speculation. 
 Another possible explanation for the decreased efficacy of AM404 relative to 
URB597 is based in another similarity between AM404 and anandamide. There is 
evidence that AM404 serves as a substrate for FAAH (Fegley et al., 2004b). Breakdown 
of AM404 by FAAH would presumably inhibit the drug’s ability to disrupt anandamide 
uptake. On the other hand, it seems that this would result in competition with anandamide 
for hydrolysis by FAAH (Di Marzo, 2006), perhaps compensating for the loss of AM404 
through its role as a substrate for the enzyme. This is again only speculation, but provides 
rationale for studies examining the consequence of combinations of a FAAH inhibitors 
and anandamide uptake inhibitors. 
 
Disparities in the effects of CP55940 and modification of AEA 
 Unlike the differences observed between the effects of URB597 and AM404, it 
was not surprising that the CB1 agonist produced a different profile of effects than 
URB597 and AM404. In fact, the prediction that this would be the case contributed to the 
rationale for Experiments 2 and 3. CP55940 is a full agonist at CB1 receptors (Pertwee, 
1999), and our findings using the hotplate, writhing, pain-suppressed feeding and wheel 
running, and schedule controlled behavior assays are consistent with the known effects of 
CB1 agonists. In addition, although we did not quantify this effect here, we can report 
that we have seen dose-dependent disruption of locomotor activity after administration of 
CP55940 which is also a well-established effect of CB1 agonists. 
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 As discussed previously, CB1 agonists activate presynaptic CB1 receptors, 
resulting in decreased synaptic activity. When administered systemically, CB1 agonists 
accomplish this throughout the nervous system. CB1 receptors are widely distributed in 
areas that are consistent with the behavioral effects of CB1 agonists. For instance, CB1 
receptors are highly expressed in brain areas related to motor control such as the basal 
ganglia and cerebellum (Herkenham et al., 1991). Likewise, CB1 receptors are elevated 
in the periaqueductal gray, dorsal horn of the spinal cord, and other regions associated 
with pain processing (Herkenham et al., 1991). This is not an exhaustive representation of 
the widespread distribution of these receptors, but these regions and associated behaviors 
have direct relevance to the current studies. In the absence of efforts to selectively 
activate CB1 receptors in areas relevant to pain processing, it is not surprising that drugs 
acting as full agonists at CB1 receptors alter locomotor activity and produce other non-
specific effects.  
 The relatively recent discovery of endogenous cannabinoids and ways to 
manipulate them has allowed for renewed targeting of the cannabinoid system for 
therapeutic goals, in addition to those of basic science. Disruption of AEA degradation by 
pharmacological means results in increased brain levels of AEA (Beltramo et al., 1997; 
Kathuria et al., 2003; Lichtman et al., 2004, 2008; Moore et al., 2005; Kinsey et al., 
2009). Accordingly, this results in increased availability of this ligand for binding to CB1 
receptors throughout the nervous system. On the other hand, there is evidence that in the 
absence of drugs, anandamide levels increase specifically in areas associated with pain 
transmission upon exposure to tonic noxious stimuli (Walker et al., 1999; Mitrirattanakul 
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et al., 2006; Jhaveri et al., 2007; Petrosino et al., 2007; Richardson et al., 2008; 
Kaufmann et al., 2009).  
 The mechanisms of noxious stimulus-induced increases in anandamide are 
unknown, and could be the result of increased synthesis or decreased metabolism of 
AEA. In any case, this presents a potentially parsimonious explanation for the apparent 
selectivity (i.e. antinociception but not other CB1 agonist-like effects) of drugs like 
URB597 and AM404. Though these drugs result in wide ranging increases in AEA 
levels, this effect may be amplified in areas relevant to pain processing because tonic 
exposure to noxious stimuli results in increased AEA in these areas.  As a result, whereas 
systemically administered CB1 agonists have their effect wherever CB1 receptors are 
located, URB597 and AM404 would have an exaggerated effect in areas where AEA 
levels are already increased. There are limited studies examining this hypothesis but one 
study that examined the effects of URB597 on AEA levels in spinal nerve ligation (SNL) 
and sham-operated rats (Jhaveri et al., 2006) found that SNL-operated rats had higher 
levels of anandamide in their ipsilateral paw compared to sham-operated animals. This is 
indicative of noxious stimulus-induced increases in AEA. On the other hand, compared to 
sham-operated rats that received URB597 injections into the ipsilateral paw, SNL-
operated rats that received the FAAH inhibitor had decreased AEA levels. In contrast to 
these findings, when URB597 was applied directly to the spinal cord of SNL-operated 
rats, they exhibited increased levels of AEA relative to sham-operated rats that received 
URB597. The mechanisms behind these disparate findings are unclear and this is an area 
that is the focus of ongoing research, but this study does suggest an interaction of FAAH 
inhibition and pain state on AEA levels. 
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 Anandamide’s activity as a partial agonist at CB1 receptors might also account for 
the fact that drugs such as URB597 and AM404 do not produce effects such as 
disruptions of locomotor activity or catalepsy. It is noteworthy that though URB597 was 
effective in three of the four pain assays utilized here (acetic acid-induced writhing, pain-
suppressed feeding, and pain-suppressed wheel running), all of these assays rely on the 
same noxious stimulus (i.p. injection of acetic acid). The acetic acid writhing model is 
known to be relatively sensitive to analgesics and on their own, the present findings 
might be indicative of this. For instance, all of the drugs tested were effective, to some 
degree, at inhibiting the writhing response. When it was possible to compare the ED50 of 
a drug in the writhing assay to the ED50 for that drug in another model, all of the drugs 
were more potent at inhibiting writhing than affecting behavior in the other models. This 
is not direct support for the hypothesis that anandamide’s partial agonist profile is why 
drugs like URB597 and AM404 do not cause the full array of CB1 agonist-like effects, 
but is consistent with some existing evidence. Other researchers have shown that partial 
and full exogenous agonists (as defined in vitro) at CB1 receptors share some behavioral 
effects (antinociception), differ in efficacy and potency on other endpoints (effects on 
thermoregulation), and can be differentiated according to the presence or absence of other 
effects (diuretic effects; Paronis et al., 2009).  
 The differing effects of CP55940, URB597 and AM404 in our studies might also 
indicate the importance of the type of the noxious stimulus in determining the 
antinociceptive effects of drugs and drug combinations. The thermal noxious stimulus 
used in the hotplate assay and the chemical noxious stimulus used in the writhing, pain-
suppressed feeding, and pain-suppressed running assays differ with regard to stimulus 
  
93 
 
modality and duration (acute versus tonic). In addition, the hotplate and writhing assays 
rely on different sites of nociceptive processing; the hotplate assay relies on spinal and 
supraspinal processing (Morgan et al., 1989; Pastoriza et al., 1996) whereas there is 
recent evidence that peripheral anandamide mediates the response to acetic acid (Clapper 
et al., 2010). Any number and combination of these variables could contribute to 
differences between the effects of the cannabinoid agents. 
 
Involvement of Endogenous Cannabinoids in the Antinociceptive Effects of Opioids 
It is well established that CB1 agonists can enhance the effects of opioids and the results 
of the present studies with CP55940 are consistent with previous findings; however, the 
mechanisms by which this occurs are yet to be identified. Researchers have hypothesized 
that one factor in cannabinoid/opioid interactions is that exposure to cannabinoids and 
opioids results in reciprocal changes in receptor expression and/or function. Behavioral 
studies relevant to this hypothesis have yielded contradictory results. Studies have shown 
cross tolerance between opioids and cannabinoids (Thorat and Bhargava, 1994; Rowen et 
al., 1998; Massi et al., 2001), as well as cross sensitization (Rubino et al., 1997). These 
behavioral phenomena may indicate changes at the receptor level, but the differing results 
of these studies do not clarify the identity of the mechanisms involved in interactions 
between the cannabinoid and opioid systems.  
 Vigano et al. (2005) attempted to reconcile these differences by examining the 
antinociceptive effects of morphine and CP55940 in rats that had received chronic 
administration of CP55940 and morphine, respectively. In addition, they attempted to 
correlate their behavioral findings to changes at the receptor level. Chronic exposure to 
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morphine produced sensitization to the antinociceptive effects of CP55940, whereas 
chronic exposure to CP55940 resulted in cross tolerance to the antinociceptive effects of 
morphine. They also found that chronic exposure to morphine decreased CB1 density, but 
increased, or did not change (depending on brain region) CP55940 activity on cAMP. On 
the other hand, chronic exposure to CP55940 resulted in increased -opioid receptor 
density, and decreased DAMGO activity on cAMP. The findings of this study suggest 
that the interactions of cannabinoids and opioids are not necessarily symmetrical, but 
clearly demonstrate that cannabinoids and opioids can alter the amount and efficiency of 
receptors of the other system. These studies provide some interesting insights into the 
behavioral and physiological consequences of chronic exposure to cannabinoids and 
opioids, but all of the present studies used acute administration of the drugs, so the results 
obtained by Vigano et al. (2005) might not be entirely relevant to our findings. 
 Another possible mechanism behind cannabinoid/opioid interactions, which is not 
exclusive of the hypothesis above and may be more relevant to our studies, is that the 
administration of drugs that act on the cannabinoid and opioid systems alter the release 
and/or synthesis of endogenous ligands for receptors of the other system. Researchers 
studying the modulation of the cannabinoid system by endogenous opioids have obtained 
results that are consistent with this hypothesis. The cannabinoid agonist 9-
tetrahydrocannabinol and morphine interact synergistically in assays of antinociception 
(Cichewicz and McCarthy, 2003; Cox et al., 2007), and kappa opioid receptor antagonists 
have been shown to attenuate the effects of cannabinoid agonists (Smith et al., 1994a; 
Pugh et al., 1995). Finally, it has been demonstrated that cannabinoid agonists increase 
dynorphin levels (Mason et al., 1999b, 1999a). Together, these findings provide strong 
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support for the hypothesis that antinociception produced by cannabinoid agonists is 
mediated by dynorphins. 
 Our studies provide indirect support for the hypothesis that endogenous 
cannabinoids are released in response to opioid administration, and thus mediate the 
antinociceptive effects of opioids. These experiments show that a selective CB1 
antagonist attenuates the antinociceptive effects of morphine. In addition, using doses and 
pretreatment times that have been shown to produce significant elevations in anandamide 
levels (Fegley et al., 2005), we demonstrated that URB597 enhanced morphine 
antinociception in preclinical pain assays that utilize acetic acid as a noxious stimulus. 
Other recent studies have found similar findings. Pacheco et al. (2008, 2009) also saw 
attenuation and enhancement of morphine’s antinociceptive effects by a selective CB1 
antagonist and FAAH inhibitor, respectively. In addition, acute administration of 
morphine increases anandamide levels in rats (Vigano et al., 2004). Taken together, these 
results are consistent with the hypothesis that endogenous cannabinoids acting at CB1 
receptors modulate the antinociceptive effects of morphine. Together with results of 
studies demonstrating interactions at the receptor and signal transduction level, these 
studies suggest a complex relationship between two biological systems that are of great 
importance and interest. 
 
Preclinical Assessment of Antinociception 
 As stated previously, a secondary goal of this project was to examine the potential 
of preclinical pain models that measure pain-suppressed behavior relative to more 
traditional models of pain-elicited behavior. At a basic science level, it is widely accepted 
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that it is important to measure nociception and antinociception across a variety of 
endpoints, behavioral and otherwise, as this can be an important determinant of the 
efficacy and potency of an intervention. The development and evaluation of assays of 
pain-suppressed behavior is an extension of this thinking.  
 A more functional perspective argues for the potential of such models based on 
the fact that they might be less susceptible to certain confounds associated with more 
traditional models (e.g. disruption of the subject’s ability to make the pain-elicited 
response). In addition, it could be argued that these models are more in line with what 
occurs at the clinical level. In humans (Melzack, 1975) and animals (Institute of 
Laboratory Animal Research, Commission on Life Sciences, National Research Council, 
1996), clinical assessment and treatment of pain is often based on the degree to which the 
pain state disrupts behaviors that would otherwise occur at a high rate. 
 Regarding the issue of confounds, it is likely that assays of pain-suppressed 
behavior are less susceptible to certain confounds associated with assays of pain-elicited 
behavior. If a drug specifically produces antinociception, it would allow pain-suppressed 
behaviors to return to baseline levels. On the other hand, if administration of a drug 
results in effects that inhibit the animals’ ability to produce the measured response (e.g. 
disruption of locomotor activity), the pain suppressed behavior would not likely return to 
baseline levels. This is an advantage of such models; however, these models aren’t 
without potential confounds of their own. In fact, the most obvious potential confound is 
basically the opposite phenomena. The effect of interest in models of pain-suppressed 
behavior is blockade of the suppression of behavior by pain (i.e. the ability of behavior to 
return to baseline levels). As a result, the researcher must determine if a return to baseline 
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is due to antinociception or drug-induced stimulation of the target behavior. For instance, 
in experiment 2, if URB597 significantly increased feeding behavior in the absence of a 
noxious stimulus, interpretation of its effects on pain-suppressed feeding behavior would 
be difficult. Thus, as would be expected, the use assays of pain-suppressed behavior does 
not eliminate the possibility of confounds or the need for careful experimental design and 
appropriate controls. 
 Another issue, with regard to the translational potential of assays of pain-
suppressed behavior, is that it is not always the case that an increase in pain-suppressed 
behavior is a desirable or reasonably attainable outcome. Sometimes antinociception in 
the absence of a resumption of behavior is sufficient. In such situations the utility of 
models of pain-suppressed behavior would be greatly diminished. 
 A final consideration, from the perspective of the experimenter, has to do with the 
practicality of the studies. The advantages of assays of pain-elicited behavior such as the 
hotplate and tail-flick assays include 1) the fact that they require little to no training of the 
animal and do not require a great deal of time, 2) there are (typically) no special animal 
housing or care requirements, 3) a variety of noxious stimuli are easily administered, and 
4) despite the statements above regarding the rationale for assays of pain-suppressed 
behavior, the confounds associated with these models are addressed fairly easily.  
 Regarding point 1, in the present studies, the pain-suppressed feeding assay did 
not require any training and in many ways (e.g. habituation to the testing room and 
apparatus, handling, etc) the procedure was similar to that that our laboratory uses for 
hotplate and tail-flick studies. Likewise, wheel-running requires no training, however, 
one obstacle that was initially encountered was that the injection procedure severely 
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disrupted running behavior (i.e. saline injections suppressed running) until mice were 
well-habituated to handling and injections. This does not take away from the validity of 
the results obtained here, but whereas the hotplate is a fairly high throughput behavioral 
model, the wheel-running assay, as designed here, requires far more time.  
 Many behavioral models (pain and otherwise) that use laboratory animals require 
special housing and care (point 2). Typically, assessments of the antinociceptive effects 
of drugs in assays of pain-elicited behavior do not warrant this; animals can be group 
housed and there is no need for special dietary considerations. The assays of pain-
suppressed behavior used here each have one of these requirements. In the feeding model 
the mice were food deprived, and in the running model the mice were individually 
housed. As stated above, these requirements are not beyond those faced by many 
researchers, but compared to assays like the hotplate, they result in decreased efficiency. 
 Another advantage of traditional assays (point 3) is the ease with which a variety 
of noxious stimuli can be administered and thus examined. As discussed above, the 
nature (modality, duration, etc.) of noxious stimuli can be an important determinant of the 
antinociceptive effects of drugs. Therefore it is desirable for researchers to study drug 
effects across a range of nociceptive endpoints. Traditional assays of pain-elicited 
behavior accommodate this quite well. However, at this stage in their development, 
assays of pain suppressed behavior are only amenable to noxious stimuli that are 
tonically active.  
 Proponents of assays of pain-suppressed behavior often mention the confounds 
that are associated with assays of pain-elicited behavior when discussing the rationale for 
the former models (point 4). Although these arguments are valid, in reality, confounds 
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such as disruptions of locomotor activity can be addressed fairly easily. Assays such as 
the rotorod assay and assessments of locomotor activity require little training or special 
care, and are very informative about whether or not a potential analgesic compound is 
actually disrupting the animals ability to produce the measured response in assays of 
pain-elicited behavior. 
 These considerations are only meant to be an objective assessment of the potential 
utility of assays of pain-suppressed behavior. The results of the present studies are 
indicative of their usefulness in detecting antinociception in the absence of non-specific 
effects, but it would be very premature to consider them as a replacement for tradition 
preclinical pain assays. Nonetheless, it is important for researchers to continue to 
consider and develop new ways of examining nociception and antinociception. 
 
Concluding Remarks 
 The experiments described herein detail efforts to contribute to the understanding 
of the role of the cannabinoid system in behavior, particularly in the behavioral effects of 
opioids. These studies reveal that acute disruption or enhancement of endogenous 
cannabinoid activity alters the antinociceptive effects of morphine, and that these effects 
are dependent on the behavioral endpoint by which they are examined. This dissertation 
expands on extensive ongoing research that continues to detail the many roles of the 
endogenous cannabinoid system. 
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